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A new structure-activity relationship (SAR) approach to modeling was utilized to 
study mammary gland carcinogens. A set of chemicals tested for mammary tumorigenesis 
that have been analyzed in the Carcinogenic Potency Database (CPDB) were subjected to 
several computational analyses in an attempt to predict each chemical’s carcinogenic 
potential. A total of six learning sets (rat and mouse mammary gland carcinogen, CPDB rat 
and mouse, and female-specific rodent models) were developed and validated using a SAR 
modeling algorithm called categorical-SAR (cat-SAR). The predictive cat-SAR program 
evaluates active and inactive compounds of known biological activity and predicts their 
biological activity from this categorical data. Overall, this study demonstrates the usefulness 
of cat-SAR and its successful application in developing ‘structural alerts’ to breast 
carcinogenicity. The resulting rat and mouse mammary carcinogen models achieved an 
82.0% (sensitivity 76.7%; specificity 87.5%) and 80.6% (sensitivity 80%; specificity 81.8%) 
concordance between experimental and predicted results, respectively. Likewise, the general 
CPDB mouse and rat models were both 70% predictive. Corresponding sensitivity and 
specificity values were 74.2 and 66.7% and 70.4 and 68.5%, respectively. The analyses 
indicate the capability of cat-SAR in identifying molecular fragments that potentially interact 
with cellular components present only in the targeted cell type (e.g., breast tissue cells). 
Moreover, this method is expected to help pre-determine structural alerts to carcinogen-
induced mammary cancer. Identification of these ‘structural alerts’ can assist in 
understanding mechanisms involved in making a normal breast cell cancerous. Using the 
results of these analyses, it is possible to classify and rank structurally diverse chemicals as to 
their potential to induce mammary gland cancer. 
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CHAPTER 1. INTRODUCTION 
 
According to the National Cancer Institute (NCI), about one in seven women in 
America will be diagnosed with some form of breast cancer during her lifetime, a rate that 
has increased over the last six decades from 1 in 22 (Ries et al.; NCI 2004). Breast cancer 
when compared to other types of cancer is the most diagnosed and prevalent cancer in 
women worldwide. Unfortunately, since the rate is increasing it has been estimated that 
breast cancer will account for 28% of all female cancers by 2012 (Hodgen et al 2002). The 
breast cancer genes, BRCA1 and BRCA2, account for only five percent of all breast cancer 
cases (Davis et al 1995). Furthermore, female BRCA1 or BRCA2 mutation carriers have a 
lifetime risk of breast cancer of between 50% and 80% (Martin et al 2000). While ionizing 
radiation, diet, nulliparity, smoking, late childbirth, and genetic factors account for at best 
47% of cases (Madigan et al 1995), there is reason to speculate that exposure to industrial 
(e.g., organochlorines and pesticides), pharmaceutical, and some plant products (e.g., 
phytoestrogens) may play a role in the rising number of breast cancer cases (Davis et al 
1993). An upper estimated limit of 80% of all cancer cases has been pinpointed to the 
environment (Tomatis et al 2001). However, it is important to note that finding plausible 
direct links between any type of cancer and the environment is complex.   
Additionally, the Congressionally Directed Medical Research Program (CDMRP) 
statistics reports that there are 192,000 established new cases of breast cancer each year, 
resulting in 40,200 deaths (CDMRP 2004). The current cycle of funding includes more than 
$150 million for breast cancer research. Also according to the CDMRP, the American Cancer 
Society figures for 2004 show that approximately 216,000 women in the United States are 
projected to receive a diagnosis of invasive breast cancer. Thus, the assessment of breast 
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cancer is a major public health concern that must be given immediate attention.  Hence, this 
study is being conducted for several important reasons.  
First of all, current methods of high-dose animal cancer bioassays do not provide 
enough information to assess human cancer risks at the usual levels of exposure (Gold et al 
2002). Humans are exposed to a myriad of potentially harmful environmental agents at 
relatively low doses. Hence, a cost-effective and rapid tool may be useful in the screening 
and prioritization of environmental chemicals (e.g., commercial products such as pesticides, 
cosmetic ingredients, nutritional supplements, and food additives).  These include high-
production volume chemicals (HPVCs) that are produced or imported in quantities exceeding 
1 million pounds per year. The United States Environmental Protection Agency (U.S. EPA) 
has noted 87,000 chemicals to be screened for endocrine disruption and other toxicological 
phenomena (EPA 2002).  Furthermore, a typical drug takes ten to twelve years and costs up 
to $500 million to reach the market, it is clearly important to discover potential toxicity in 
silico as soon as possible (Dearden 2003). By establishing an estimated risk posed by groups 
of environmental chemicals it may be possible to control their exposure or to facilitate the 
synthesis of safer consumer products. 
Secondly, the study presented herein will attempt to predict the fate and effects of 
such chemicals on human and animal health via a new computational method called 
categorical-SAR (cat-SAR). In addition to developing highly accurate models, the cat-SAR 
program presents a better explanatory power in comparison to other SAR approaches. The 
final suitably validated SAR models of this study may have significant utility as a two-
dimensional screening tool, to the extent that large datasets of untested candidate compounds 
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can now be rapidly assessed and prioritized for subsequent toxicological evaluation as 
mammary carcinogens.  
Thirdly, it has been hypothesized that endocrine-disrupting chemicals (EDCs), 
particularly, synthetic estrogenic environmental contaminants (e.g., xenoestrogens) are linked 
to an increased incidence of breast cancer in women. EDCs (e.g., bisphenol A and 4-
nonylphenol) mimic the action of the female steroid hormone 17-β-estradiol, which is 
primarily responsible for the development of the female reproductive system (Crisp et al 
1998). However, there have been conflicting epidemiological data regarding the role of 
xenoestrogens in breast cancer development (Safe 1995; Falck 1992; Ashby 1997). Most 
research studies do not support the hypothesis that there is a link between exposure to 
environmental chemicals, particularly endocrine-disrupting chemicals (EDCs), and the 
increasing incidence of breast cancer (Safe 2004).  Hence, the underlying relationship 
between carcinogens and estrogens was investigated.   
Governmental and public concern over the high prevalence of structurally diverse 
chemicals some of which are toxic to humans, especially chemicals present in consumer and 
industrial products, medicines, foods, the workplace, and the environment has now surfaced 
as one of the most pressing issues of interest.  The National Toxicology Program (NTP) was 
established in 1978 to coordinate research and testing of potential human carcinogens and to 
publish the Report on Carcinogens, which lists human carcinogens (Bennett and Davis, 
2002). SAR models have been accepted by regulatory agencies worldwide, including the 
U.S. EPA, for risk assessment. Predictive and mechanistic SAR models have shown to be 
highly reliable in terms of assessing untested chemicals for toxic potential and understanding 
how they may induce toxicity.  
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For this study, an attempt was made to yield the best concordance between 
predictions and experimental results. It is proposed that the approach described herein will 
curtail the stupendous amount of time, cost, and use of animals involved in bioassays to 
assess these compounds on a regulatory basis. The SAR analysis should thereby provide 
further insight into the extent (if at all) xenoestrogens potentially play in the etiology of 
breast cancer. The hypothesis for this study is that specific attributes of certain chemicals are 
related to their ability to induce breast cancer. In summary, the goals and objectives of this 
study are as follow: 
(i) Evaluate a new SAR technique called cat-SAR in identifying structural alerts of 
carcinogenesis. 
(ii) Identify structural alerts for rodent and mammary-specific carcinogenesis. 
(iii) Investigate the mechanistic underpinnings of mutagenesis and estrogenicity and 
their potential involvement in breast cancer development.  
The stated goals were achieved via use of the cat-SAR program in conjunction with 
Tripos Sybyl Holographic Quantitative Structure-Activity Relationship (HQSAR) modeling 
software. Of importance, the approach described herein helps determine relatedness (i.e., 
structural overlap) among different toxicological endpoints such as rodent carcinogenesis, 
female and breast-specific carcinogenesis, estrogenicity, and mutagenesis by examining a 
random sample of 10,000 chemicals of unknown biological activity. This group of 
compounds derived from chemical structure libraries and from a random sample of chemical 
structures from the NCI is representative of all chemicals in the environment. The prevalence 
of chemicals predicted to possess the ability to induce multiple biological effects 
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simultaneously should provide a measure of the mechanistic relatedness of these 












































CHAPTER 2. LITERATURE REVIEW 
 
2.1 Breast Cancer Development  
 
Breast cancer is a broad term used to describe various types of cancer that occur in 
the breast. Like most other common and life-threatening epithelial malignancies, human 
breast cancer presents itself clinically after a prolonged multi-stage process of 
carcinogenesis. Breast tumors are most likely to arise in the epithelial cells that line the 
mammary glands and ducts and are associated with several carcinogen exposures including 
radiation, diethylstilbestrol (DES), and estrogens (Brown et al 1995). Mammary gland 
growth and development are mediated through the complex interactions of steroid hormones, 
polypeptide hormones, growth stimulatory factors, and growth inhibitory factors (Haslam et 
al 2003).  
Breast cancer is very uncommon in women under the age of thirty-five, but it is 
prevalent in women over the age of fifty, and the risk is especially high for women over age 
sixty (Ganz 2001). Ettinger et al have proposed that women (usually women over age 35) 
using estrogen replacement therapy have a higher risk of breast cancer, although the levels do 
not reach statistical significance (Ettinger et al 1996). Moreover, it is evident that long-term 
users of hormone replacement therapy (HRT) and those exposed to high doses of estrogen 
may slightly increase the risk of breast cancer ((Brinton et al 1993). In support of this, a 
recent study presented findings that show a hyperproliferative effect of HRT on mammary 
epithelial cells (Le Marchand 2004). Some researchers have reported a greater risk of breast 
cancer in postmenopausal women receiving combined estrogen plus progestin HRT than in 
those receiving estrogen alone that may indicate a significant role for progesterone in 
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mammary cancer (Stadel 2002). However, little is known about risk from the frequently 
prescribed estrogen/progestin combination. 
Despite ongoing human epidemiological studies, the exact causes of breast cancer 
remain unknown. This is due to the complexity of carcinogenesis and the endocrine system. 
The endocrine system is composed of a number of elements (e.g., receptors, chemical 
messengers, and the synthetic apparatus) and actions (e.g., transcriptional (i.e., genomic) and 
non-transcriptional (i.e., non-genomic) mechanisms of signal transduction through steroid 
hormone receptors, homeostatic mechanisms, etc.)), all of which may play a role in the 
development of breast cancer (Simoncini et al 2003). Additionally, it has been presumed that 
certain structural attributes of estrogens are associated with metabolic transformation to 
mutagens that are highly engaged in mitogenesis (Davis et al 1993). Mitogenesis (i.e., cell 
proliferation) is one of the many mechanisms of cancer-causation. Estrogens have the natural 
ability to cause mitogenesis which makes it favorable to try to relate xenoestrogen exposure 
to breast cancer (Davis et al1993). However, xenoestrogens also have the potential to induce 
mammary cancer by exerting genotoxic or epigenetic effects on DNA via their possible 
biotransformation to free radicals (Liehr et al 1990). Roy and others have shown an elevated 
level of 8-hydroxyguanine through free radical generation of the prototype carcinogenic 
estrogen DES (Roy et al 1991). 
Primary carcinogenesis may also occur with other xenobiotics because human breast 
epithelial and fibroblastic cells metabolize them to carcinogenic electrophiles (Davis et al 
1993). For example, estradiol metabolism proceeds primarily through two mutually exclusive 
pathways, each of which is affected by xenobiotic exposures: Pathway I to 2-hydroxyestrone 
(2-OHE1), which has minimal estrogenic activity and is non-genotoxic, or Pathway II to 1-
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alpha-hydroxyestrone (1-α-OHE1), a fully potent estrogen which is also genotoxic (Davis et 
al 1993). Breast cancer risk appears to be linked with these two pathways. This strengthens 
the reasoning behind attempting to link estrogenicity to breast carcinogenicity. Alterations of 
mammary gland development and to cellular proliferation from chemical exposure could 
alter cancer susceptibility (Brown et al 1995). To understand cancer it is important to know 
what happens when and how normal cells become cancerous, especially since it has already 
been noted that a dividing cell is much more at risk for mutation than a quiescent cell (Huff 
et al 1991).  
2.2 Steroidal, Non-steroidal, and Synthetic Estrogens 
 
It is noteworthy to introduce and review the different types of estrogens that humans 
are faced with as a large number of chemicals possess estrogenic activity and therefore, are 
possibly involved in breast cancer development. Although synthetic estrogens may be linked 
to breast cancer in women, there is a need for natural steroidal estrogen in female sexual 
maturation and growth (e.g., alter the distribution of body fat to produce body contour and 
other secondary characteristics). Additionally, high levels in some cells bring about 
pigmentation in the region of the nipples and areolae and in the genital region (Katzung 
2004). Many steroidal estrogens are known as human carcinogens and are a class of 
hormonally active compounds derived from cholesterol with the primary purpose to control 
reproductive function and growth characteristics (IARC 1997). About 40% of all cancers in 
women are hormonally mediated (Henderson et al 1991). It has been proposed that these 
agents are associated with an increased breast cancer incidence in both women and men in 
the industrialized world (Katzung 2004). 
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In addition to the variety of steroidal estrogens derived from animal sources, 
numerous non-steroidal estrogens have been synthesized. Many phenols are estrogenic and 
estrogenic chemicals have been identified from diverse forms of life including those found in 
ocean sediments. Estrogen-mimetic compounds (bioflavonoids) are found in many plants as 
well, including saw palmetto and soybeans and other foods (Setchell 1985).  The plant 
bioflavonoids include different structural classes of compounds, which contain a flavonoid 
backbone: flavones, flavanones, flavonols, isoflavones, and related condensation products 
(e.g., coumesterol) (Safe 1995). 
An example of a non-steroidal estrogen, albeit pharmaceutical or antiestrogenic, is the 
most extensively used breast cancer drug, tamoxifen. Tamoxifen is a competitive partial 
agonist inhibitor of estradiol at the estrogen receptor used in the treatment of advanced breast 
cancer in postmenopausal women. Another synthetic and highly potent non-steroidal 
estrogen and known human carcinogen is DES, which was distributed to some 2 to 3 million 
women experiencing complications with their pregnancies between 1943 and 1971. As a 
result, hundreds of female offspring of women treated with DES have been diagnosed with 
clear cell adenocarcinoma (i.e., transplacental carcinogenesis) (Katzung 2004).  
Some synthetic chemicals or intermediates that have been identified as estrogenic 
compounds include bisphenol A, a chemical used in the manufacture of polycarbonate-
derived products, contaminants of phenol red solution, a pH indicator used in cell culture 
media, and alkyl phenols and their derivatives, which are extensively used for preparation of 
polyethoxylates in detergents (Safe 1995).  Polychlorinated biphenyls (PCBs) and 1,1-
dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) (a by-product of the pesticide DDT) are the 
two most researched organochlorine pollutants identified in all human tissues with high 
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frequencies. It should be noted that several hydroxylated PCBs bind to the estrogen receptor 
(ER), and it is possible that para-hydroxylated PCB metabolites may be the active estrogenic 
compounds associated with lower chlorinated PCBs. Some studies have reported that several 
additional organochlorine pesticides including endosulfan, toxaphene, and dieldrin exhibit 
estrogenlike activity and induce proliferation of estrogen responsive MCF-7 human breast 
cancer cells (Safe 1995). 
2.3 Probable Modes of Action  
 
There exist several ‘structural alerts’ or functional groups that may be associated with 
chemical mutagenesis and carcinogenesis. For carcinogenicity in humans, it is known that the 
vast majority of chemicals that cause cancer in humans are genotoxic, meaning that they 
attack DNA and pose as potent carcinogens. In contrast to human carcinogens, which are 
primarily organ-specific, most genotoxic rodent carcinogens are not species-specific or 
tissue-specific. It is noteworthy, however, that these chemicals represent the potential for 
either entering directly into electrophilic reaction with deoxyribonucleic acid (DNA) or being 
biotransformed by metabolism into an electrophilic functionality that can react with DNA 
(Ashby et al 1989). Increasing attention is now being given to the proven genotoxic and 
carcinogenic potential of endogenous estrogen metabolites especially 4-hydroxylation of 
estrogen to 4-hydroxy estrone (4-OH-E), via the cytochrome P450 enzyme, CYP1B1, which 
can form within and subsequently transform mammary epithelial cells independent of their 
estrogen receptor (ER) status (Butterworth et al 1992). Estrogens exert their physiological 
effects via the ER, which functions as a ligand-activated transcriptional regulator. ER is a 
member of a large family of nuclear receptor transcription factors with a characteristic 
modular structural organization with distinct domains associated with transactivation, DNA 
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binding and hormone binding. It is also an important pharmaceutical target for hormone 
replacement in menopausal women and for chemotherapeutic drugs against certain 
reproductive cancers (Pike et al 1999).  
As described by Davis and others, “certain xenoestrogens, broadly defined in the 
literature as being basically hormone-mimicking compounds, may promote cancer by 
enhancing the production of “bad” estrogens. Other xenoestrogens may act by binding to the 
estrogen receptor and inducing it to issue unneeded proliferative signals.” Chemicals with 
these properties may encourage the development of cancer in additional ways as well. For 
example, “there are indications that some xenoestrogens promote angiogenesis thus 
providing the blood vessels needed for tumor growth and spread (Davis et al 1993); others 
seem to damage DNA (i.e., mutagens)” (Davis et al 1995). Exposure at certain times may 
also heighten the carcinogenic effects of xenoestrogens (Davis and Bradlow 1993).  
 In addition to lifelong exposure to endogenous estrogen produced by the ovaries in 
pre-menopausal years and by aromatase conversion of androgens in post-menopausal years, 
susceptible breast epithelium may also be exposed to additive promoting doses of exogenous 
estrogen in the form of HRT, or to the as yet unproven in vivo promoting effects of 
environmental xenoestrogens (Davis et al 1993). Of importance, xenoestrogens are a 
relatively diverse group of compounds that do not lend themselves readily to typical SAR 
analysis.  
2.4 Rodent Cancer Bioassay 
 
Although, a large variety of compounds currently in general use are analogs to known 
mammary carcinogens for rodents, few have been tested for their carcinogenic potential 
(Coyle 2004). Approximately half of all chemicals tested, whether synthetic or natural, with 
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animal bioassays are carcinogenic to rats or mice at relatively high doses (Ames et al 1995). 
This suggests that there are a large number of chemicals in the environment presenting 
themselves as health hazards and the only acceptable method for testing is the rodent cancer 
bioassay. To date, the EPA has endorsed no commercial prediction system as a replacement 
for legally mandated testing of a toxicity health endpoint, although predictions can be 
submitted for consideration in overall chemical evaluations (Richard 1998). The reliability of 
rodent carcinogenicity assays is usually ascertained by repeating experiments with the same 
substance under the same test conditions (Gottmann et al 2001). However, given the cost of 
$2 -3 million and the three to five years required for planning, testing, and subsequent data 
analysis of a single chemical in a lifetime rodent carcinogenicity bioassay, “initial decisions 
on whether to continue development of a chemical, to submit pre-manufacturing notice 
(PMN), or to require additional testing may be based largely on structure-activity relationship 
models and short-term assays” (Klaassen 2001).  
The standard two-year rodent bioassay used to determine the carcinogenicity is 
usually carried out on the suspected chemical at the maximum tolerated dose (MTD). The 
MTD can be defined as an estimate of the highest dose of an agent administered to a test 
animal in a chronic study that will not modify longevity from effects other than 
carcinogenicity. Due to this, it is speculated that these carcinogenic chemicals, most of which 
stem from industry, are carcinogenic and/or mutagenic at low doses in humans. Without 
further relevant data, this has to be considered true for human risk assessment. Simply, 
without data on mechanism of action for a given chemical, the true risk of cancer at low dose 
is highly uncertain, even for rats or mice (Gaylor et al 1995). By manipulating the 
experiment, “more than 90% of all chemicals can induce some tumor in a rodent” (Furst 
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1991). Pitfalls encountered in bioassays result from “not specifying the exact agent under test 
and how it relates to human exposure, using inappropriate routes of administration unrelated 
to humans, administering high doses, or concluding that a cancer was induced without 
adequate histopathological description of the lesion” (Furst 1991). Although the focus of this 
study was not geared toward uncovering the problems of in vivo assays, such pitfalls must be 
taken into consideration before any conclusions based on the results of this study can be 
drawn.  
2.5 Comparison of SAR and QSAR Models 
 
SAR has been applied both in a qualitative way (e.g., as simple recognition of 
structural alerts), and in a quantitative way (e.g., QSAR) to build mathematical models 
linking the physical chemical or structural properties of the molecules to the toxicological 
endpoints (Benigni et al 2004). The EPA has historically relied upon SAR for screening new 
chemicals for adverse health effects under the Premanufacture Notification Review 
requirements of the Toxics Substances Control Act (TSCA) (Wagner et al 1995). The EPA 
defines structure-activity relationship (SAR) as the relationship of the molecular structure of 
a chemical with a physicochemical property, environmental fate attribute, and/or specific 
effect on human health or an environmental species.  
An SAR analysis can be either qualitative (SAR) or quantitative (QSAR). An SAR 
study seeks to identify the essential features of chemical structure that are determinants of a 
biological activity from available structural and bioassay information (Richard 1995).  This 
implicitly assumes a causal relationship between fundamental molecular properties and 
activity in the bioassay under study, even when details of the mechanism of action are 
unknown (Richard 1995). According to the EPA, the difference between the two lie in that 
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qualitative SAR predictions are based on a comparison of valid measured data from one or 
more analogs (i.e., structurally similar compounds) with the chemical of interest. For 
example, categorical terms such as “similarly toxic”, “less toxic”, or “more toxic” would be 
used in a qualitative SAR assessment for toxicity to humans or environmental species. 
Quantitative predictions, on the other hand, are usually in the form of a regression equation 
and would thus predict dose-response data as part of a QSAR assessment (EPA 2002). Both 
SAR approaches can be applied to mechanism-based studies. 
2.6 Expert Systems 
 
Computational models with good predictive capability can be generated and several 
of these computational tools utilize substructural moieties (i.e., fragments) for identifying 
active regions of the molecules (White et al 2003). However, to date, assessments for health 
endpoints have been based primarily on chemical analogy and expert judgment and not on 
commercial prediction systems (Wagner et al 1995). The phrase “expert system for 
predicting toxicity” is used in various ways in the literature. Henceforth, for the purposes of 
this thesis, an expert system (ES) for predicting toxicity is considered to be “any formalized 
system, not necessarily computer-based, which enables a user to obtain rational predictions 
about the toxicity of chemicals” (Dearden et al 2003).  
Therefore, in these terms, an expert system is a computer program that “provides 
solutions to important problems similar to those obtained by human experts” (Benfenati et al 
1997). There are two classes of expert systems: (1) automated approaches that rely on the use 
of statistics in determining correlations between chemical structure and biological effect 
(machine learning programs); and (2) knowledge-based systems that rely on a set of 
programmed rules distilled from available knowledge and human expert judgment (Richard 
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1998). These two categories of approaches differ in the ways that they represent, process, and 
generalize chemical-biological activity information. Some commercially available toxicity 
prediction programs are DEREK, CASE/MultiCASE, TOPKAT, and ONCOLOGIC.  
The CASE/MultiCASE program falls under the first category. The MCASE 
(Klopman and Rosenkranz 1994) and TOPKAT (Enslein 1994) approaches rely upon 
statistical or automated algorithms for extracting SAR associations from existing data, with 
little or no prior application of expert judgment or organization of data according to 
mechanism or chemical class. The ONCOLOGIC (Woo et al 1995) and DEREK (Sanderson 
and Earnshaw 1991; Greene 1996) approaches, in contrast, are rule-based systems built 
almost entirely upon prior knowledge, heuristics, expert judgment, and chemical and 
biological mechanism considerations (Richard 1999). DEREK makes qualitative rather than 
quantitative predictions by looking for previously characterized structural alerts and their 
associated toxic activity (Benfenati et al 1997). ONCOLOGIC has a typical structure 
consisting of a large number of rules that are combined together in order to give specific 
answers to specific questions pertaining to carcinogenicity (Woo 1998). 
It is important to note that each individual toxicity prediction must be judged based 
not only on the statistical performance of the model (e.g., overall model sensitivity, 
specificity, accuracy), but also on the strength of the mechanistic or molecular analogy 
argument supporting the prediction. EPA’s revised cancer Risk Assessment Guidelines, for 
example, specifically encourages the use of SAR information provided that it strengthens an 
argument based on “biological plausibility” and “mode of action consistent with generally 
agreed upon principles and understanding of carcinogenicity” (Richard 1999). Some of the 
benefits of an expert system are summarized as follow:  
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(i) Captures expertise before it is lost via use of existing data derived from  
 
human knowledge (e.g., DEREK and TOPKAT) 
 
(ii)  Reduces dependence upon one expert 
(iii)  Reduces errors and inconsistencies 
(v) Increases knowledge-sharing 
(vi) Expedites decision-making and may assist in the formulation of policies 
Toxicity prediction systems are much more capable of, and useful for, identifying a 
potential toxicity hazard than they are at ruling out a hazard (Richard 1998). SAR models, in 
general focus primarily on determining the mechanistically bounded requirements for an 
activity, (i.e., identifying structural alerting features for activity). Lack of activity, 
representing a fundamentally unbounded condition, is most often predicted by the absence of 
activating features (Richard 1998). Although the methodology prescribed with expert 
systems involve computers, human expertise must be incorporated into the modeling process. 
In other words, good data is essential for SAR modeling and human experts are needed to 
define what data is actually good data. Also, once the computer-generated model makes 
predictions, a human expert familiar with the biology of the endpoint being tested is needed 
to interpret the data and draw acceptable conclusions. It is important to remember that SAR 
models are based upon toxicological testing and the ultimate goal is not always to replace 
animal testing, but to support the data and use mechanistic-based SAR modeling as an aiding 
tool to help in the prioritization of the vast amount of untested chemicals. 
2.7 SAR Models as Classifiers 
 As of the last decade, SAR modeling has emanated as a useful tool in the screening of 
large, complex and noncongeneric (dissimilar) compounds. The historical success of its use 
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along with the experimental reproducibility of the rodent bioassay results in toxicological 
studies has triggered further research in the area. Hence, in addition to providing mechanistic 
data that’s explainable by current knowledge, predictive SAR models present hypothetical 
cases. The cat-SAR approach as well as other SAR approaches, have been developed by 
ruminative evaluation of existing experimental rodent carcinogenicity results.  For example, 
the models in this study were based on the toxicological results outlined by Gold and others 
in the Carcinogenic Potency Data Base (CPDB) (Gold et al 2001).   
SAR models attempt to classify groups of chemicals based on their structural features 
that may or may not be associated with one or more biological activities. Hence, SAR 
datasets must be evenly balanced (Linusson et al 2000). If it is not, the applied learning set 
may consist of unbalanced data and a SAR model may be developed that has high sensitivity 
and low specificity yielding a high number of false positives or low sensitivity and high 
specificity yielding a high number of false negatives (Walker et al 2003). The goal is to have 
a high rate of prediction. However, risk attitudes govern the use of toxicity prediction 
systems for hazard identification and screening (Richard 1998). In assessing a toxicity 
hazard, a false negative prediction is much more costly from a risk management standpoint 
than a false positive prediction. For instance, if a chemical is determined to be safe and is 
allowed on the market there can be ecological and human consequences, whereas, a false 
positive prediction cost will be primarily in revenue for shareholders of a corporation if they 
had intended to market the product.  
In respect to the cat-SAR approach, prediction accuracies are assessed on the basis of 
overall concordances with the CPDB carcinogenicity classifications of positive 
(carcinogenic) or negative (noncarcinogenic).  For instance, the reproducibility of the CPDB 
 18
and Salmonella mutagenicity data are 75% (Gold 1991) and 85% (Zeiger 1985), respectively. 
Hence, these accuracies can be considered as estimates of the top accuracy reachable by any 
SAR method studying the toxicological phenomena. Most SAR approaches to 
carcinogenicity predictions share a clear limitation. That limitation is that they produce high 
sensitivities and low specificities. In other words, the prediction system incorrectly predicted 
many non-carcinogens as positive. It is believed that this may be due to the presence 
unbalanced datasets. The cat-SAR program, however, addresses this limitation by employing 
an optimization scheme.  
2.8 Influence of Structural Diversity of Datasets on Model Prediction  
 
The greatest challenge faced by users and designers of SAR programs is being able to 
predict carcinogenicity for a wide diversity of molecular structures, spanning an 
undetermined number of chemical classes and biological mechanisms (Richard et al, 2002). 
Whereas a drug design study deals with a well-defined class of congeneric chemicals that 
induce a well-defined biological activity, in toxicology one often deals with a certain 
biological effect (e.g., mutation, cancer) that can be induced by chemicals very different from 
each other (i.e., noncongeneric chemicals) (Benigni et al 1994). This recognition of the 
inherent biological and chemical compartmentalization of the carcinogenicity prediction 
problem as consisting of a large number of mechanistically distinct or overlapping sub-
problems, is necessary for formulating effective solutions to the general prediction problem, 
as well as for understanding the limitations and successes of current approaches (Richard 
1999).  
The study presented herein is an attempt to determine the relationship between 
environmental chemicals and mammary carcinogens and evaluate the robustness and 
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predictability of the newly developed cat-SAR program.  The evaluation of the SAR 
approach employed herein serves as a valuable illustration of its application for toxicity 
prediction. The results will be used to draw conclusions about the link between several end-
points in terms of structural make-up. Furthermore, the derivation of final suitably validated 
cat-SAR models in this area may have significant utility as a two-dimensional data base 
searching tool, to the extent that large data bases of candidate molecules can now be rapidly 
screened and prioritized for compounds that should undergo subsequent toxicological 
evaluation as breast carcinogens. It will be seen from the findings in this study that the 
conclusions regarding mechanistic relatedness among toxicological phenomena can be 
















CHAPTER 3. MATERIALS AND METHODS 
3.1 Cat-SAR Study: Introduction  
 
As mentioned, the categorical-SAR (cat-SAR) methodology is a new in silico 
approach to modeling toxicological phenomena. The program serves as a powerful analysis 
tool that can identify significant structural features that may be responsible for the 
experimental activity (i.e., mammary carcinogenicity) and inactivity (i.e., non-mammary 
carcinogenicity) of test compounds for a specific endpoint. For the purposes of this study, the 
toxicological endpoints evaluated were breast-specific and rodent carcinogens. The 
fundamental concept of the program is that if a substructure correlates with the experimental 
active chemical, it will be present primarily in active compounds in the dataset. On the other 
hand, if it is not related to the experimental activity, it will be randomly dispersed amongst 
active and inactive compounds of the database.  
The program’s capability in determining a compound’s potential for being a 
carcinogen was assessed through the leave-one-out cross-validation (LOO-CV) procedure. 
LOO-CV is a re-sampling method used to assess the predictivity and stability of SAR models 
where one test compound is removed and the remaining compounds are used to predict its 
activity. Basically, the program involves a series of interrelated steps that when combined 
generate objective and unbiased models. The cat-SAR evaluation occurs in the following 
order: (1) database construction and molecular modeling, (2) in silico fragmentation of the 
learning set, (3) LOO-CV, (4) prediction, and (5) mechanistic analysis. Succinctly, the 
process begins by gathering a hierarchy of information by simply separating and classifying 
the learning set in question into relevant or purposeful chemical categories (e.g., carcinogens 
and noncarcinogens). The second step involves the entry of binary response data in terms of a 
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particular compound’s biological activity (e.g., “1” corresponds to positive and “0” to 
negative compounds). The assigned value for classes of test compounds can be any whole 
number with the goal of making a clear distinction between different classes of test 
compounds. It should be noted that these values are not representative of the chemical’s 
potency or toxicity level.  
Foremost, this method is an attempt to enhance the general understanding of 
chemical-induced etiology of breast cancer. As previously mentioned, the main goal behind 
the proposed methodology is basically two-fold: (i) to investigate the potential that 
environmental chemicals may be involved in the development of breast cancer and (ii) to 
evaluate the cat-SAR algorithm. It was speculated that the approach employed in this study 
would provide a clear distinction between mammary and non-mammary gland carcinogens 
and noncarcinogens.  
3.2 Methodology 
 
3.2.1 Carcinogenic Potency Database (CPDB) 
 
Toxicological data were obtained from the CPDB compiled by Gold et al. (Gold et al 
2001). The CPDB analyzes and consolidates into a single resource the world's diverse 
literature on chronic, long-term animal cancer bioassays (Gold et al 1995). Analyses of 6073 
experiments on 1458 chemicals (i.e., positive or negative for carcinogenicity), that have been 
reported in Technical Reports of the National Cancer Institute/National Toxicology Program 
(NCI/NTP) or in papers in the general published literature are presented (Gold et al 2001). 
Therefore the CPDB consists of two different subsets, the results from the NCI/NTP and the 
results from the general literature. The CPDB plot standardizes the experimental results 
(whether positive or negative for carcinogenicity), including qualitative data on strain, sex, 
route of compound administration, target organ, histopathology, and the author’s opinion and 
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reference to the published paper, as well as quantitative data on carcinogenic potency, 
statistical significance, tumor incidence, dose-response curve shape, length of experiment, 
duration of dosing, and dose rate (Gold et al 1999). This systematic route was taken to better 
investigate the relationship between the identified structural alerts and its carcinogenic 
activity.  
Furthermore, a potency value for carcinogens, the TD50 is calculated. Gold and 
collaborators, in a simplified way, defined a TD50 as that dose rate in mg/kg body wt/day, 
which, if administered chronically for the standard life span of the species, will halve the 
probability of remaining tumorless throughout that period (Gold et al 1999). Stated 
differently, a TD50 is that daily toxic dose that is required to induce tumors in 50% of the test 
animals. For this approach, the categorizing of potency values involved either a “0” or a “1” 
where a 1 was simply assigned to those chemicals reported as carcinogens (i.e., assigned a 
TD50 value in the CPDB) and a 0 to those designated as noncarcinogens (i.e., chemicals 
without a TD50 value). This is termed a categorical approach to modeling. 
Using this data, a general rat (946 chemicals), mouse (763 chemicals), rat female (723 
chemicals), mouse female (738 chemicals), and several sets of rat (100 mammary 
carcinogens) and mouse (24 mammary carcinogens) mammary gland carcinogen models 
were constructed. Each of these models contained an “active” and “inactive” category. . In 
summary, the following mammary databases were created: 1) a model of mammary 
carcinogens (MC) categorized as the “active chemicals” and non-mammary carcinogens 
(NMC) as the “inactive chemicals”. Hence, referred to as the “MC-NMC” model and 2) a 
model comprised of MCs and whole animal noncarcinogens (NC). However, for the mouse 
dataset, instead of using a random set of mouse noncarcinogens, a random set of rodent 
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noncarcinogens were used. Thus, this model was termed the “MC-NC” model for the rat and 
“MC-RNC” for the mouse. The reason for considering two distinctive “inactive” categories 
(i.e., NC and NMC categories) for the rat and mouse mammary carcinogen models is to 
assess organ-specific carcinogenesis (i.e., breast carcinogenesis) by distinguishing between 
the activating and inactivating fragments of breast carcinogens from that of noncarcinogens 
and also from carcinogens that do not induce breast carcinogenesis. This approach aids in 
demonstrating that the set of mammary carcinogens in question are in fact inducing tumors in 
the mammary gland and not just a chance occurrence of predicting mammary cancer. 
Moreover, to eliminate the possibility of attaining a “true model” via chance 
occurrence, models for each fragment set of randomly selected “inactive” compounds, albeit 
noncarcinogens or non-mammary carcinogens were constructed in multiples of three. In 
other words, three models were produced for both the MC-NMC and MC-NC models. With 
respect to the rat MC-NMC and MC-NC models, each model contained the same 100 rat 
mammary carcinogens (MC), as outlined in the CPDB (Gold et al 2001), representative of 
the model’s “active” category. However, three of these models contained 100 randomly 
selected rat noncarcinogens (NC) as the “inactive” category. The other three models were 
comprised of 100 randomly selected non-mammary gland carcinogens (NMC) (i.e., general 
rat carcinogens) for its “inactive” category.  
Likewise, of the 48 chemicals that comprised each of the three mouse MC-RNC and 
MC-NMC learning sets, 50% were listed in the CPDB as mouse mammary gland carcinogens 
(i.e., the model’s “active” category). Hence, each of the six mouse mammary carcinogen 
models contained these 24 MCs as the model’s “active” category. On the other hand, three of 
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the models constructed contained 24 randomly selected rodent noncarcinogens (RNC) as the 
“inactive” category as previously described.  
3.2.1.1 Selection of Mammary Carcinogens 
 
The mammary carcinogen models are based on all mammary carcinogens in the 
CPDB. Overall, the CPDB mouse and rat mammary gland consisted of 24 and 102 
chemicals, respectively. Of the 102 rat mammary gland carcinogens (including several male-
only breast carcinogens), 100 were suitable for our present analysis. Due to program 
restrictions on complex polymers, racemic mixtures, technical-grade chemicals, metals, 
metaloorganiccompounds, and complex inorganic compounds, norlestrin (a complex 
mixture) and dimethylaminoethylnitrosoethylurea, nitrite salt were excluded from the 
learning set. Moreover, organic salts were included as the freebase. Simple and defined 
mixtures and technical grade compounds were included as their major or active component. 
All of the 24 CPDB mouse breast carcinogens met our set criteria and hence, all were 
included in the database. An equivalent number of non-carcinogens were then randomly 
obtained and added to the rat and mouse databases giving rise to a total of 48 mouse 
chemicals (50% active and 50% inactive compounds) and 200 rat chemicals (50% active and 
50% inactive compounds). 
3.2.1.2 Selection of Mammary Noncarcinogens 
 
The mouse noncarcinogens (i.e., “inactive” category) were randomly selected from a 
database of 47 chemicals tested to be inactive (no observed tumor induction) in rodents. 
However, due to the small number of chemicals that tested negative in both the rat and 
mouse species, we were unable to mesh the 100 rat mammary gland carcinogens with an 
equivalent number of rodent noncarcinogens. So instead, a total of 100 rat noncarcinogens 
were randomly selected from a set of 449 CPDB chemicals tested negative in only the rat 
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species. Likewise, for the rat mammary-specific model, a set of 100 compounds was 
randomly selected from a total of 395 (excluding the 100 mammary carcinogens) CPDB 
carcinogens all of which did not induce mammary tumors in the rat species.  
Furthermore, to assure random assortment of the “inactive” category of the models, 
three sets of random selection was performed for each rat and mouse mammary-carcinogen 
model constructed. It should be noted that each inactive chemical in the learning set had an 
equal opportunity of being selected. For example, after selecting a group of chemicals from 
the dataset to represent the “inactive” category of the model, these chemicals were placed 
back into the pool of noncarcinogens for a second draw. This was repeated until all three 
models were comprised of an equal set of noncarcinogens. The rationale behind this 
approach was to ensure model consistency among random inactive subsets of the database. 
Hence, each of the models constructed is an illustration of the “true model” which 
demonstrates how stable (or consistent) the individual model estimates are.  
This multiple random sampling also helps in determining the dependency of the 
model on the dataset on which it was built. This procedure helps: 1) eliminate to some extent 
the representation bias in the database due to its composition and random selection, 2) 
determine the variability and stability of the resulting SAR models derived from random 
samplings of the empirical distribution, 3) identify the most consistent model, and 4) 
determine the overall reliability of the “true model” on the dataset from which it was built.  
3.2.1.3 General Rat and Mouse Learning Sets 
 
Two databases containing all tested rat and mouse chemicals (actives and inactives) 
that met our set criteria were also developed, fragmented into all possible fragments, and 
underwent validation and prediction by the cat-SAR program. Again, data used to build these 
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models were entirely based on information gathered by Gold and others in the year 2001 plot 
of the CPDB (Gold et al 2001). The rat model contained 946 compounds in which 447 were 
inactive compounds and 499 actives. The mouse model contained 769 chemicals in which 
386 inactive chemicals and 383 active chemicals. It was then expected that a greater number 
of structural alerts would be generated due to the size of these learning sets. The rodent 
mammary gland models discussed earlier are subsets of these general models. Stated 
differently, the compounds analyzed in the rat mammary gland models were also considered 
in the general rat model. The same is true for those carcinogens and noncarcinogens 
contained in the female mouse mammary gland models. 
3.2.2 Database Construction 
 
Just like all SAR approaches the cat-SAR approach begins with a given set of 
chemical compounds with their known structures and associated biological activity. The cat-
SAR datasets are composed of its chemical name, molecular structure, and categorical label 
(i.e., “0” or “1”). Tripos® SYBYL6.8 Holographic Quantitative Structure-Activity 
Relationship (HQSAR©) molecular modeling software package (Tripos Associates, Inc., St. 
Louis, Missouri) was used for the in silico fragmenting of all learning sets of chemicals into 
all possible fragments whereas cat-SAR was used to do all SAR modeling and statistical 
analyses of compounds, validations, and predictions of chemical toxicity. 
3.2.2.1 Significance of Balanced cat-SAR Datasets 
 
For SAR studies, the chemical composition of learning sets is of critical importance. 
Most databases publicly available for the development of SAR models are not equally 
distributed (e.g., most often toxicologically-active chemicals pre-dominate) (Rosenkranz and 
Cunningham 2001). By having an equal number of inactive and active compounds in our 
models ensures that we can apply the “common-sense” or “weight-of-evidence” approach to 
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analysis. Additionally, a more accurate and optimal observed correct prediction (OCP) rate is 
expected. However, as seen with the general rat model this statement does not hold true. To 
avoid experiencing the problem of having a high presence of carcinogens predicted correctly 
and also a high number of noncarcinogens being predicted incorrectly due to a greater 
concentration of carcinogens versus noncarcinogens in the data set, the cat-SAR system can 
be adjusted to account for this indifference.  
3.2.2.2 Model Parameters 
 
Unlike most SAR approaches, the structural property of a fragment that goes into the 
final model is what drives the model to make a prediction and not the chemical compounds 
from which they originated. In cat-SAR, the ability to adjust fragment parameters (e.g., atom, 
bonds, connections, hydrogen atoms, chirality, and donor and acceptor) of the model can lead 
to an enhanced quality of the output data for the model. For this study, a hologram length of 
151 was arbitrarily used for each of the models created and only the atoms (A), bonds (B), 
connections (C), and/or hydrogen (H) as a fourth parameter was selected. A fragment size of 
3 to 7 heavy atoms (e.g. excluding hydrogen atoms) was selected for the derived models and 
compounds were designated as inactives (e.g., noncarcinogens with significantly inactive 
fragments) and actives (e.g., carcinogens with significantly active fragments). The various 
modeling parameters that can be adjusted by the user make the cat-SAR algorithm a more 
flexible program by providing greater opportunities to ascertain the relationship between 
chemical structure and toxicological activity thus separate it from existing commercial SAR 
programs. 
The biological activity associated with each fragment was determined later in the 
study. This was done by examining the fragment parts of a chemical as it appears in the 
validation summary and based on weight-of-evidence we will be able to determine if a 
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chemical contains significantly more active than inactive fragments. From this observation, it 
was reasonable to conclude that a chemical was active versus inactive based on its 
significantly high presence of active molecular fragments (e.g., weight-of-evidence). This 
made it feasible to say that a particular chemical is indeed active or inactive based on its 
fragment composition. In other words, the selection of mechanistically important molecular 
descriptors can possibly reveal or relate to the structural basis for toxicological activity or 
inactivity. 
3.2.3 In silico Fragmentation of Test Compounds 
 
Upon completion of the initial fragment list for the learning sets, a Tripos SYBYL 
Add-on script was utilized for fragment counting. The Add-on script associates each 
fragment with all the molecular compounds in which it was found in the form of a tabulated 
compound-fragment matrix for each set of fragments (e.g., “ABC” and “ABCH” fragment 
sets). As previously stated, each fragment is labeled with the name and activity of its parent 
chemical. Upon completion of this process, cat-SAR organizes the list of fragments and 
tabulates the number of chemicals containing each of them (Figure 3.1). In other words, the 
generated fragments are examined by cat-SAR for its association with the toxicological 
endpoint in question. The fragment list will be used in investigating the mechanisms and also 
in predicting the activity of untested chemicals as well as compounds with unknown 
biological activity. The number of active and inactive compounds containing a specific 
fragment was then calculated.  
Those chemical compounds containing “insignificant” fragments according to the set 
criteria will be excluded from the final model. Insignificant fragments are those structures 
within the initial model that are either: 1) unique, 2) found approximately equivalent in active 
and inactive compounds, and 3) did not meet the other user’s criteria (discussed in next 
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subchapter). For example, the chemical fragment may be so unique that the fragment was 
only listed in one or two chemicals and thus, not predicted. However, chemicals that were 
found to contain “significant” active and inactive fragments or ‘structural alerts’ by the 
program will serve as the basis for the final model’s make-up. Moreover, it should be noted 
that the selection of “significant” fragments utilizes the “Common Sense” approach and not 
statistical analysis. 
3.2.4 Set Criteria: cat-SAR Rules 
 
3.2.4.1 Selection of Significant Fragments 
 
To establish a link between each molecular fragment and its associated activity and 
inactivity, a set of rules were derived for the selection of “significant” active and inactive 
fragments. The first selection rule entails the frequency or occurrence of the fragment’s 
appearance in the dataset under consideration. This was conceptually set at three chemicals 
for all learning sets under evaluation. The primary reason for setting the cut-off point at three 
is to possibly ‘rule out’ or exclude those unique fragments that may not serve as being useful 
in terms of determining the overall structure-activity relationship. Based on this cut-off, in 
order for the program to call a given fragment a “significant” active or inactive (i.e., 
fragments used to make predictions), that fragment must first be identified in a minimum of 
three chemicals in the learning set. Hence, the exclusion of rare fragments makes the model 
more mechanistically informative. 
To assess the phenomenon of possible exclusion of active and inactive structural 
alerts, it was presumed that any requirement less, or due to the small datasets, greater than 
three, would require fragments found by chance to be included in the model. This restricts 
the probability of losing rather important information (e.g., certain structural features) about 
a particular model. In other words, it was presumed that if the models were made too 
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restrictive taking into consideration the small size of the learning set (e.g., requiring a 
fragment to be found in more than three compounds), then vital information about the model 
could very well be lost in the process. However, it is noteworthy to mention that all 
fragments that fall outside this criterion are not necessarily “insignificant”. This concept 
should not be over-looked as the number of cases in which those fragments found in one or 
two of the test compounds was simply inadequate in number and thus, not used by the 
program. The possibility of having “significant” fragments excluded from the final model 
based on this rule will be further analyzed. 
The second selection rule involved the learning set’s distribution of active and 
inactive compounds linked to a particular fragment. To fulfill the requirements of this rule, 
two proportions, 0.75 and 0.90 models, were developed for both the ABC and ABCH 
fragment sets. For instance, at a cut-off of 75%, if a fragment were present in twenty 
chemicals in the learning set it would have to be found in at least fifteen active or inactive 
chemicals to be considered a significant fragment. However, when set at 0.90, the selection 
process becomes more stringent as a fragment must now be found in at least ninety percent of 
the total number of active or inactive compounds in the learning set, and also meet the 
requirement of the first rule in order for it to be identified as either a “significant” active or 
inactive chemical. In other words, this criterion in comparison to the 75% proportion imposes 
a stricter requirement when selecting the “significant” fragments from the total pool of 
fragments. 
It is important to note that the very same fragments are being used for both the 0.75 
and 0.90 proportions. Hence, all the generated fragments listed in the 0.90 proportions will 
also be found in the 0.75 proportions. Once again, the user selects these proportions. If the 
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criteria set by the user are not met, those fragments are assumed to be “insignificant” and will 
be excluded from the final model (composed of only “significant” active and inactive 
fragments). As a result of this screening process, a much smaller fragment set is generated 
and will go into constructing the final model.  
Moreover, it was reasoned that if a particular fragment is associated with activity, 
there may yet be other reasons (i.e., fragments) for it being inactive, thus it would not be 
expected to be found in 100% of the active compounds. Likewise is true for inactive 
fragments. Thus, if consideration was based largely on fragments found exclusively in active 
or inactive compounds, the fragment pool is rarified to an unacceptable level and there is an 
associated risk of the model becoming less information-intensive (i.e., loss of important 
information). Of importance, fragments found equally in active and inactive compounds are 
also eliminated. Such fragments may serve as chemical scaffolds holding the biologically 
active features and are not directly related to activity or inactivity (Cunningham et al; in press 
2005).  
In summary, fragments were considered “significant” if they were found in at least 
three compounds in the dataset and depending on the model, also found in at least 75% or 
90% of the active or inactive compounds that derived them. The ensuing “significant” 
fragments are used in predicting the toxicity of a test compound and also for mechanistic 





Figure 3.1 Tripos Sybyl HQSAR fragment-embedded molecular spreadsheet illustrating 
fragments 12,278 through 12,281 out of the 14,941 total generated fragments with coded 
atoms from the rat MC-NC model. 
 
3.2.5 Model Predictions 
 
The cat-SAR model determines if the molecule in question contains an active or 
inactive fragment from the model’s dataset. The program does this by operating on a 
“weight-of-evidence” where a chemical is screened for fragments listed in the significant 
fragment list and whether or not it is categorized as an active or inactive depends on its 
structural composition. Briefly, if more fragments are found that are inactive versus active, 
then this compound will be predicted as inactive and vice versa. For example, if a compound 
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contains two fragments, one based on 5/6 inactives (i.e., fragment was found in 5/6 inactive 
compounds) and the other fragment was found in 3/3 active compounds in the model’s 
learning set, then this unknown compound will be predicted by cat-SAR to have an 89% (i.e. 
8/9) chance of being inactive for this endpoint. This is the probability of activity for that test 
compound. Likewise, the compound will have an 11% (i.e., 1/9) chance of being inactive. 
Hence, the probability of activity or inactivity can be computed on the basis of a test 
compound’s fragment composition. In other words, this approach allows the probability of 
activity and inactivity to be determined by comparison of the structure of the test chemical 
against the entire structural information present in the model. Furthermore, if the model is 
unable to link any of the “significant” active or inactive fragments to a test compound, then 
no prediction is made for that compound. 
3.2.6 Model Validations  
 
The validation of SAR models is important because it assesses the model’s reliability 
(Walker et al 2003). Herein, the models created for each database were tested for robustness 
and reliability. In order to estimate each model’s quality, the cat-SAR algorithm adopted the 
LOO procedure to cross-validation. In these validation procedures, each chemical was 
removed from the complete dataset of chemicals (n), one at a time, leaving (n-1) chemicals 
as the learning set. This probability of activity or inactivity for each chemical was 
recalculated using the (n-1) database as the learning set. In other words, an SAR model was 
constructed from the remaining 99% of the chemicals. At this point, all molecular fragments 
from the (n-1) set are used in calculating the probability of a chemical being active or 
inactive. The LOO-CV procedure was repeated on each test compound using the reduced 
fragment set (i.e., the group of fragments that met the set criteria) n times until each 
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compound had been tested. As previously mentioned, the probability of activity or inactivity 
determines the model’s prediction of a test compound. Hence, it is possible to determine the 
overall probability of activity or inactivity to be used in categorizing a chemical as either a 
carcinogen or noncarcinogen. This enables the user, based on the results from the LOO-CV, 
to select and apply an optimal cut-off point that aids in the separation of predicted active and 
inactive compounds. Validations were performed for each database. The cat-SAR approach 
is applicable to various learning sets of dissimilar compounds.  
3.2.6.1 Statistical Evaluation: Sensitivity, Specificity, and OCP 
 
The two concerns addressed when studying the cat-SAR models were: (1) the 
predictive capability of the model, and (2) the consistency of the model form. The success of 
a predictive SAR model can be described in a combination of ways. In general, the validity 
of SAR models based on learning sets is assessed by the sensitivity, specificity, and 
concordance (i.e., observed correct predictions (OCP)) statistics when describing 
phenomena. 
 Simply put, the sensitivity is defined as the number of correct positive predictions 
out of the total number of positive predictions made. The sensitivity of a model expresses the 
ability of the model to accurately predict a true positive chemical as positive, i.e., in the 
present carcinogenicity study, carcinogenic (Walker et al 2003). In contrast, specificity is the 
total number of correct negative predictions out of the total number of negative predictions 
made. The specificity of a model expresses the ability of the model to accurately predict a 
true negative chemical as negative, i.e., in the present study, noncarcinogenic (Walker et al 
2003).  
On the other hand, the concordance (i.e., OCP rate) is defined as the number of 
correct predictions (i.e., correctly predicted active and inactive test compounds) out of the 
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total number of predictions made. Generally the results of this study summarized concordant 
and discordant classifications (carcinogen and noncarcinogen) attained by the cat-SAR 
program. The sensitivity and specificity of the SAR models developed herein were 
determined by the removal of a test compound from the database.  
3.2.7 Mechanistic Rationalization: Chemical Diversity Approach 
  
While the objective of this study attempts to support the widely studied hypothesis 
that models designed in silico are as valuable as animal bioassays, it was necessary to 
determine, if any, mechanistic overlap occurring between models of different toxicological 
endpoints (i.e., Salmonella mutagenicity, carcinogenicity, mammary-specific carcinogenicity, 
and estrogenicity). Furthermore, while reliable databases of toxicological phenomena, when 
available, are usually small in chemical content, the approach used herein predicts the 
toxicological profiles of 10,000 chemicals (Rosenkranz et al 2000). The “Chemical Diversity 
Approach” (CDA) operates on the assertion that the mechanistic relationship between 
toxicological phenomena can be determined on the basis of the prevalence of chemicals 
tested in an assay to have the same biological activity. These chemicals were derived from 
chemical structure libraries and from a random sample of molecular structures from the 
National Cancer Institute Repository of potential cancer chemotherapeutic agents 
(Cunningham et al 2004). By employing the CDA, it was possible to analyze the potential of 
chemicals demonstrating breast carcinogenicity in the standard rodent assay to be possibly 
related to other toxicological phenomena such as mutagenicity and estrogenicity. 
The applicability of this approach is that while no SAR model is perfectly predictive, 
when applied to a population of 10,000 chemicals, provided the sensitivity and specificity are 
approximately equal we can expect that the overall prevalence will reflect the true 
distribution (Rosenkranz et al 2000). This allows a determination of the significance of the 
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observed joint prevalences. Under the assumption (i.e., the null hypothesis), that there is no 
relationship between the two or more toxicological phenomena under investigation, the 
observed joint prevalence of chemicals that induce both phenomena could then be compared 
with the expected joint prevalence. If the observed prevalence is significantly greater than the 
expected one, then it can be concluded that the two phenomena are related to one another 
mechanistically. Similarly, if the observed prevalence is significantly lower than the expected 
one, it suggests that the two phenomena are antagonistic with one another, e.g., they could 
compete for an active site. 
In implementing such an approach, mechanistic insight into the breast carcinogenicity 
phenomenon is gained by evaluating the concordance, or lack thereof, between biological 
endpoints. For instance, the CDA is applicable when considering the mechanistic relationship 
between agents that are Salmonella mutagens and those that cause the breast carcinogenicity 
phenomena (i.e., mitogenesis and binding to the estrogen receptor). Additionally, the 
approach can be used to confirm specific hypotheses (e.g., the electrophilic theory of cancer 
causation) as well as to generate new (i.e., knowledge-based) hypotheses driven solely by the 
data and the availability of appropriate SAR models (Rosenkranz et al 2000). 
3.2.8 Overview of cat-SAR Method 
In review, two toxicological phenomena were studied. The first phenomenon was 
cancer and the other was mammary-specific carcinogenesis. All data was taken from the 
2001 version of the CPDB (Gold et al 2001) and all statistical analysis was performed with 
the cat-SAR algorithm (see Tables 1-8). For each learning set, an ABC (atoms, bonds, and 
connections) and ABCH (atoms, bonds, connections, and hydrogen) sets of fragments were 
created. These sets are important in fragment distinction. Furthermore, each generated model 
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consisted of an “active” and “inactive” category. The varying predictive performance of 
these groups assisted in identifying an optimal model. The CDA is then applied to the 
resulting optimal models and a group of 10,000 noncongeneric (i.e., dissimilar) chemicals to 








































CHAPTER 4. RESULTS AND DISCUSSION 
 
4.1 Study Results 
 
4.1.1 Predictability of cat-SAR Mammary Carcinogen Models 
 
 The models assessed for predictivity were the rat and mouse ABC and ABCH 
mammary carcinogen-non-mammary carcinogen (MC-NMC) and the mammary carcinogen-
non-carcinogen (MC-NC or MC-RNC) models. During LOO-CV, sensitivity, specificity, and 
concordance values of the models were established. Through LOO-CV, the rat MC-NMC 
ABC 90% model presented the best predictivity. This model attained a sensitivity of 83% 
and a specificity of 74% yielding a concordance of 79% (ABC 3/0.90 Model 1, Table 4.1). 
Predictions were made on 124 of the chemicals in the learning set (Table 4.5). 
Table 4.1 Predictive performance summary for the rat mammary–non-mammary carcinogen 
(MC-NMC) cat-SAR model.  The ABC model was based on fragments of size between three 
and seven heavy atoms and considered atoms, bonds, and atom connections. The ABCH 
model included consideration of hydrogen atoms. 



















ABC 3/0.75        
Model 1 13868 1349 849 500 0.80(70/88) 0.66(53/80) 0.73(123/168) 
Model 2 14461 1330 861 469 0.72(63/87) 0.72(59/82) 0.72(122/169) 
Model 3 14427 1245 767 478 0.68(59/87) 0.74(64/86) 0.71(123/173) 
Average 
ABC 3/0.90 
14252 1308 825 482 0.73(64/87) 0.71(59/83) 0.72(123/170) 
Model 1 13868 1102 731 371 0.83(58/70) 0.74(40/54) 0.79(98/124) 
Model 2 14461 1086 723 363 0.82(54/66) 0.69(44/64) 0.75(98/130) 
Model 3 14427 847 520 327 0.82(51/62) 0.72(41/57) 0.77(92/119) 
Average 
ABCH 3/0.75 
14252 1012 658 354 0.82(54/66) 0.71(42/59) 0.77(96/124) 
Model 1 32235 3679 2081 1598 0.81(78/96) 0.62(55/89) 0.72(133/185) 
Model 2 32374 3921 2088 1833 0.70(66/94) 0.64(59/92) 0.67(125/186) 
Model 3 32627 3497 1928 1569 0.75(70/93) 0.69(65/94) 0.72(135/187) 
Average 
ABCH 3/0.90 
32412 3699 2032 1167 0.76(71/94) 0.65(60/92) 0.70(131/186) 
Model 1 32235 2750 1642 1108 0.81(65/80) 0.76(50/66) 0.79(115/146) 
Model 2 32374 2947 1637 1310 0.75(55/73) 0.69(53/77) 0.72(108/150) 
Model 3 32627 2241 1170 1071 0.81(63/78) 0.70(52/74) 0.76(115/152) 
Average 
 
32340 2646 1483 1163 0.79(61/77) 0.72(52/72) 0.76(113/149) 
Footnotes 
            (table cont.) 
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Total Fragments: number of fragments derived from learning set. 
Model Fragments: number of fragments meeting specified rules of the model. 
Active Fragments: number of fragments meeting specified rules to be considered as active. 
Inactive Fragments: number of fragments meeting specified rules to be considered as inactive. 
Sensitivity: number of correct positive predictions/total number of positives predicted. 
Specificity: number of correct negative predictions/total number of negatives predicted. 
Observed Correct Predictions:  number of correct predictions/total number of predictions. 
Likewise, the best rat MC-NC model with the best predictive performance was the 
ABC 90% model. This model was able to achieve a concordance between experimental and 
predicted results of 82% with a sensitivity of 77% and a specificity of 88% (ABC 3/0.90 
Model 2, Table 4.2).  For this model, predictions were made on 145 of the 200 chemicals in 
the dataset (Table 4.6). As noted, both rat MC-NC and MC-NMC models favored the stricter 
requirement (i.e., a proportion of 90%).  
Table 4.2 Predictive performance summary for the rat mammary carcinogen – 
noncarcinogen (MC-NC) cat-SAR model.  The ABC model was based on fragments of size 
between three and seven heavy atoms and considered atoms, bonds, and atom connection.  
The ABCH model included consideration of hydrogen atoms. 



















ABC 3/0.75        
Model 1 18021 1336 758 578 0.73(66/90) 0.78(69/88) 0.76(135/178) 
Model 2 17369 1486 786 700 0.71(67/95) 0.80(72/90) 0.75(139/185) 
Model 3 15547 1629 737 892 0.69(62/91) 0.76(67/88) 0.72(129/179) 
Average 
ABC 3/0.90 
16979 1484 760 723 0.71(65/92) 0.78(69/89) 0.74(134/181) 
 
Model 1 18021 1016 642 374 0.82(62/76) 0.78(47/60) 0.80(109/136) 
Model 2 17369 1129 617 512 0.77(56/73) 0.88(63/72) 0.82(119/145) 
Model 3 15547 1311 624 687 0.83(63/76) 0.73(44/60) 0.79(107/136) 
Average 
ABCH 3/0.75 
16979 1152 628 524 0.80(60/75) 0.80(51/64) 0.81(112/139) 
Model 1 38797 3859 1790 2069 0.72(68/94) 0.76(68/90) 0.74(136/184) 
Model 2 37636 4293 2007 2286 0.71(70/98) 0.77(75/97) 0.74(145/195) 
Model 3 34407 4093 1785 2308 0.73(71/97) 0.65(62/95) 0.69(133/192) 
Average 
ABCH 3/0.90 
36947 4082 1861 2221 0.72(70/96) 0.73(68/94) 0.73(138/190) 
Model 1 38797 2746 1434 1312 0.76(63/83) 0.78(61/78) 0.77(124/161) 
Model 2 37636 2923 1392 1531 0.75(63/84) 0.78(67/86) 0.77(130/170) 
Model 3 34407 2949 1372 1577 0.74(66/89) 0.71(52/73) 0.73(118/162) 
Average 
 
36947 2873 1399 1473 0.75(64/85) 0.76(60/79) 0.76(124/164) 
Footnotes: See Table 4.1 
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The best mouse MC-NMC model selected for further analysis was the ABC 75% 
model. This model yielded a concordance of 81% with a sensitivity of 80% and a specificity 
of 82% (ABC 3/0.75 Model 2, Table 4.3). Predictions for this model were made on 42 of the 
48 chemicals comprising the dataset (Table 4.7). 
Table 4.3 Predictive performance summary for the mouse mammary carcinogen–non-
mammary carcinogen (MC-NMC) cat-SAR model with 3 to 7 heavy atoms. 



















ABC 3/0.75        
Model 1 5553 188 136 52 0.75(15/20) 0.61(11/18) 0.68(26/38) 
Model 2 4718 138 69 69 0.80(16/20) 0.82(18/22) 0.81(34/42) 
Model 3 6508 169 87 82 0.75(15/20) 0.78(14/18) 0.76(29/38) 
Average 
ABC 3/0.90 
5593 165 97 68 0.75(15/20) 0.74(14/19) 0.77(30/39) 
Model 1 5553 106 73 33 0.80(12/15) 0.50(4/8) 0.70(16/23) 
Model 2 4718 116 62 54 0.79(15/19) 0.78(7/9) 0.79(22/28) 
Model 3    6508 122 69 53 0.83(15/18) 0.67(4/6) 0.79(19/24) 
Average 
ABCH 3/0.75 
5593 115 68 47 0.82(14/17) 0.63(5/8) 0.76(19/25) 
Model 1 13517 801 591 210 0.62(13/21) 0.78(18/23) 0.70(31/44) 
Model 2 12040 655 386 269 0.81(17/21) 0.77(17/22) 0.79(34/43) 
Model 3 15187 753 434 319 0.62(13/21) 0.91(21/23) 0.77(34/44) 
Average 
ABCH 3/0.90 
13581 736 470 266 0.67(14/21) 0.83(19/23) 0.75(33/44) 
Model 1 13517 443 324 119 0.55(11/20) 0.55(6/11) 0.55(17/31) 
Model 2 12040 544 329 215 0.84(16/19) 0.74(14/19) 0.79(30/38) 
Model 3 15187 553 352 201 0.79(15/19) 0.63(5/8) 0.74(20/27) 
Average 
 
13581 513 335 178 0.74(14/19) 0.62(8/13) 0.69(22/32) 
Footnotes: See Table 4.1 
 In addition, the mouse MC-RNC model was the most predictive model and achieved 
a concordance of 81% with a sensitivity of 84% and a specificity of 76% (ABC 3/0.75 Model 
1, Table 4.4). This model made predictions on 36 of the 48 chemicals in the learning set 
(Table 4.8). In contrast to the rat MC models, these models favored the least restrictive 
requirement (i.e., a proportion of 75%). Overall, all models achieved concordances 
significantly better (χ2 =7.98, p=0.005) than chance (i.e., 50%). In fact, each of the mammary 
carcinogen models presented good predictive power indicative that the database’s structural 
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alerts are artifacts of chance-correlation, but are relevant to the specific activity or inactivity 
categories they represent. In addition, almost all chemicals from the learning sets received a 
prediction (i.e., wide coverage). This helps substantiate the validity of the cat-SAR expert 
system in developing meaningful and generalized models. 
Table 4.4 Predictive performance summary for the mouse mammary carcinogen – rodent 
noncarcinogen (MC-RNC) cat-SAR model with 3 to 7 heavy atoms. 



















ABC 3/0.75        
Model 1 6414 379 72 307 0.84(16/19) 0.76(13/17) 0.81(29/36) 
Model 2 6504 357 185 172 0.72(13/18) 0.65(11/17) 0.69(24/35) 
Model 3 6157 294 172 122 0.75(12/16) 0.83(15/18) 0.79(27/34) 
Average 
ABC 3/0.90 
6358 343 143 200 0.78(14/18) 0.76(13/17) 0.77(27/35) 
Model 1 6414 352 84 268 0.87(13/15) 0.44(4/9) 0.71(17/24) 
Model 2 6504 244 192 52 0.86(12/14) 0.40(4/10) 0.67(16/24) 
Model 3 6157 195 109 86 0.86(12/14) 0.75(6/8) 0.82(18/22) 
Average 
ABCH 3/0.75 
6358 264 128 135 0.86(12/14) 0.56(5/9) 0.74(17/23) 
Model 1 14963 1396 436 960 0.85(17/20) 0.68(13/19) 0.77(30/39) 
Model 2 15956 1502 672 830 0.63(12/19) 0.58(11/19) 0.61(23/38) 
Model 3 14819 1188 658 530 0.79(15/19) 0.79(15/19) 0.79(30/38) 
Average 
ABCH 3/0.90 
15246 1362 589 773 0.79(15/19) 0.68(13/19) 0.74(28/38) 
Model 1 14963 1346 466 880 0.72(13/18) 0.80(12/15) 0.76(25/33) 
Model 2 15956 1022 634 388 0.77(13/17) 0.65(11/17) 0.71(24/34) 
Model 3 14819 1010 607 403 0.77(13/17) 0.67(10/15) 0.72(23/32) 
Average 
 
15246 1126 569 557 0.76(13/17) 0.69(11/16) 0.73(24/33) 
Footnotes: See Table 4.1 
4.1.2 Analysis of Mammary Carcinogen Models 
To address model consistency, statistical analysis was performed on each of the three 
random selections of noncarcinogens and non-mammary carcinogens (i.e., model’s 
“inactive” category). As a reminder, all models, regardless of ABC and ABCH assortment or 
inactive category make-up, are subsidiaries of the general rat and mouse models. The random 
selection of “inactive” compounds for the rat and mouse mammary carcinogen datasets 
shows that the models (models 1-3) for each of the ABC and ABCH sets are performing 
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about the same. In other words, the models differing in only non-carcinogens are statistically 
consistent with the total number of correct chemical predictions that is being made (i.e., 
similar OCP rates). For example, the rat MC-NC ABC 90% models all achieved OCP rates 
ranging from 79-82% (Table 4.2). Similar observations were seen with the other mammary 
carcinogen models (Tables 4.1- 4.4).   Model consistency among the random subsets of 
inactive models is important because it assures that the models are not arbitrarily making 
predictions or mechanistic assertions. Despite the challenge of small datasets as presented by 
the mouse mammary carcinogen model, the cat-SAR algorithm was able to make predictions 
on a great number of compounds (i.e., greater than chance). Moreover, the models were all 
statistically consistent. 
  4.1.2.1 ABC and ABCH 75% and 90% Models 
When making comparisons between the ABC and ABCH 75% and 90% models, the 
average values for fragment count, OCP, sensitivity, and specificity values were considered. 
Based on this, it was noted that the 90% criteria for selecting important fragments from the 
rat mammary dataset presented models with better OCP, sensitivity, and specificity. 
However, it should be noted that a cost is associated with this increased accuracy. This cost is 
a limitation in the model’s mechanistic capability due to its exclusion of important fragments. 
It was observed that fewer predictions were made on chemicals with this stringent criterion. 
For example, the rat MC-NC ABC 75% model 2 made predictions on 185 chemicals in the 
learning set whereas the rat MC-NC 90% model 2 made predictions on 145 chemicals 
(Tables 4.2 and 4.8). Thus, the model is comprised of fewer significant active and inactive 
fragments possibly making the model less-information intensive. It is speculated that the 
decrease in the number of significant fragments from 1486 to 1129 (ABC 3/0.75 and 0.90 
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Model 2, Table 4.2) may be responsible for the reduction in the total number of chemical 
predictions made. 
In contrast, the much smaller mouse mammary learning set favored the 75% criteria. 
Initially, this was expected because small-sized models would be expected to generate the 
least number of fragments (i.e., less information). Thus, it was reasonable to assume that 
based solely on the small sample size (i.e., 48 compounds comprised the model), it was very 
unlikely that many of these fragments would have been found in 90% or more and in at least 
3 of the total active or inactive compounds in the learning set. Although, the mouse MC-NC 
(ABC 90%) model 3 when compared to model 1 of the ABC 75% set, has a higher OCP rate 
(Table 4.4), when comparing the two models in terms of the number of chemicals it 
predicted, model 1 was the better model overall. Simply, model 3 was a poor model to 
illustrate as such few inactive compounds were predicted. Thus, the OCP rate in addition to 
the total number of chemicals predicted by the model was justifiably taken into consideration 
when determining which of the three random subsets of inactive models was better in terms 
of its predictive power.  
Furthermore, the ABC models had a better predictive performance when compared to 
the ABCH models, which were more specific by the inclusion of hydrogen atoms. Generally, 
it was noted that going from the ABC to the ABCH model resulted in doubling of the total 
number of fragments. For example, the rat MC-NMC ABC 90% models had an average of 
14252 fragments and the ABCH model was based on an average of 32340 fragments (ABC 
and ABCH 3/0.90, Table 4.1). Similar observations were seen with the model’s active and 
inactive fragments and also the model’s total generated significant fragments (Table 4.1).   
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However, despite the doubling of significant fragments and an increase in the number 
of predictions being made, the ABCH models generally did not result in better sensitivity, 
specificity, and OCP rates. In most cases, this “doubling effect” resulted in decreased OCP 
rates of the mammary carcinogen models.  Only in few instances, the OCP rate was slightly 
improved when going from the ABC model to the ABCH model. For example, the mouse 
MC-NC ABC 3/0.90 model 2 achieved an OCP of 67% whereas its ABCH counterpart 
yielded an improved OCP of 71% (Table 4.4). However, based on the computed averages for 
the ABC and ABCH 75% and 90% models, the ABCH models did not contribute to the 
model’s enhancement of the overall predictive performance. 
Table 4.5 Model validation for rat mammary gland carcinogens and non-mammary gland 
carcinogens (MC-NMC). For the ABC model, compounds with values equal to or greater 
than 51% were predicted to be carcinogenic and those below 51% were predicted to be non-
carcinogenic. For the ABCH model, compounds with values equal to or greater than 63% 
were predicted to be carcinogenic and those below 63% were predicted as non-carcinogenic. 




 ABC  ABCH 








Experimental    
Activity (0.51) (0.63) 
1-Amino-2,4-dibromoanthraquinone + 81-49-2 - * * 
Azoxymethane + 25843-45-2 - * * 
Chloroform  - 67-66-3 - * * 
Cupferron + 135-20-6 - * * 
Dapsone - 80-08-0 - * * 
Dichloroacetylene . 7572-29-4 - * * 
Dimethyl methylphosphonate - 756-79-6 - * * 
Ethyl alcohol - 64-17-5 - * * 
N-Nitrosodiphenylamine - 86-30-6 - * * 
o-Phenylenediamine.2HCl + 615-28-1 - * * 
Z-ethyl-O,N,N-azoxyethane . 16301-26-1 - * * 
1,2-Dihydro-2-(5-nitro-2-
thienyl)quinazolin-4(3H)-one 
+ 33389-33-2 - 1 0.99 
1-Nitroso-1-hydroxyethyl-3-
chloroethylurea 
. 96806-34-7 - 0.981 0.981 
2,4,5-Trimethylaniline + 137-17-7 - 1 1 
3-Amino-1,2,4-triazole  - 61-82-5 - 0.938 0.921 
Acetaminophen - 103-90-2 - 0.979 0.887 
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Auramine O + 2465-27-2 - 1 1 
Dichlorvos + 62-73-7 - 1 1 
Hydantoin ND 461-72-3 - 0.951 0.947 
N-methyl-N’-nitro-N-
nitrosoguanidine 





51325-35-0 - 0.963 0.959 
Proflavine hydrochloride hemihydrate + 952-23-8 - 1 1 
Tris(2,3-dibromopropyl) phosphate + 126-72-7 - 1 1 
Trp-p-1 acetate . 75104-43-7 - 0.99 0.992 
2-Azoxypropane . ----------- - * 1 
Chlorofluoromethane - 593-70-4 - * * 
Thioacetamide - 62-55-5 - * * 
Tris(2-chloroethyl)phosphate - 115-96-8 - * * 
Vinyl acetate + 108-05-4 - * * 
Vinyl bromide . 593-60-2 - * * 
1-(4-Chlorophenyl)-1-phenyl-2-
propynyl carbamate 
. 10473-70-8 - * * 
2,6-Dinitrotoluene + 606-20-2 - * * 
5-Nitro-ortho-anisidine - 99-59-2 - * * 
DL-ethionine - 67-21-0 - * * 
Nitrobenzene - 98-95-3 - * * 
Trimethylthiourea + 2489-77-2 - * * 
N-methyl-N-nitrosobenzamide + 63412-06-6 - * 1 
4-Chloro-o-phenylenediamine - 95-83-0 - * * 
Benzofuran + 271-89-6 - * * 
Nitroso-baygon - 38777-13-8 - * * 
2,3,7,8-Tetrachlorodibenzo-p-Dioxin + 1746-01-6 - * * 
2-Naphthylamine  . 91-59-8 - * * 
beta-Butyrolactone - 3068-88-0 - * * 
Mirex photo + 2385-85-5 - * * 
p-Nitrosodiphenylamine + 156-10-5 - * * 
p-Quinone dioxime + 105-11-3 - * * 
Pararosaniline hydrochloride + 569-61-9 - * * 
Pentachloroanisole - 1825-21-4 - * * 
t-butyl alcohol - 75-65-0 - * * 
2,4,6-Trichlorophenol + 88-06-2 - * 0.091 
Azaserine . 115-02-6 - * 0 
Dehydroepiandrosterone . 53-43-0 - * 0 
Tamoxifen citrate + 54965-24-1 - * 0 
Urethane  . 51-79-6 - * 0 
Nitrosoamylurethane + 64005-62-5 - 1 0.544 
Nitrosoethylurethane - 614-95-9 - * 0.163 
Propylthiouracil + 51-52-5 - * 0 
Chrysazin - 117-10-2 - * 0.047 
Diethylstilbestrol + 56-53-1 - * 0.045 
     (table cont.)
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Furfural  - 98-01-1 - 0 0.9 
Furan + 110-00-9 - 0 0 
p-Cresidine - 120-71-8 - 0 0 
Uracil + 66-22-8 - 0 0 
5-Azacytidine . 320-67-2 - 0 0.109 
4-(Methylnitrosamino)-1-(3-pyridyl)-
1-butanol 
+ -------- - 0.382 0.249 
1,2-Epoxybutane . 106-88-7 - 0 0.455 
1-Nitroso-3,4,5-trimethylpiperazine + 75881-18-4 - 0.024 0.032 
1-Phenyl-3,3-dimethyltriazene + 7227-91-0 - 0.02 0.03 
4,4'-thiobisbenzenamine . 139-65-1 - 0 0 
6-Dimethylamino-4,4-diphenyl-3-
heptanone hydrochloride 
- 1095-90-5 - 0.028 0.037 
Benzene - 71-43-2 - 0 0 
Chlorobenzene + 108-90-7 - 0 0 
C.I. Direct blue 6 + 2602-46-2 - 0.504 0.613 
C.I. Direct black 38 . 1937-37-7 - 0.504 0.622 
Ciprofibrate ND 52214-84-3 - 0 0 
Clofibride + 26717-47-5 - 0 0 
D&C red no. 5 . 3761-53-3 - 0 0.004 
N,N'-dinitroso-perhydropyrimidine - 15973-99-6 - 0.032 0.037 
Ethinyl estradiol -  57-63-6 - 0 0.219 
FD&C red no.1  - 3564-09-8 - 0 0.004 
FD&C red no. 2 . 915-67-3 - 0 0.005 
Fumonisin B1 + 116355-83-0 - 0 0.051 
Hydrazine sulfate  . 10034-93-2 - 0 0.038 
ICRF 159 - 21416-87-5 - 0.059 0.061 
Methimazole - 60-56-0 - 0 0 
Methyl t-butyl ether + 1634-04-4 - 0 0 
Mitomycin C . 50-07-7 - 0.051 0.067 
N-nitroso-bis-(4,4,4-trifluoro-n-
butyl)amine 
. 83335-32-4 - 0.022 0.032 
N-Nitroso-N-methyldecylamine + 75881-22-0 - 0.028 0.033 
N-Nitrosodimethylamine  . 62-75-9 - 0.045 0.05 
N-nitroso(methyl)-(2-
hydroxyethyl)amine 
+ 26921-68-6 - 0.025 0.022 
N-Nitrosopiperazine . 5632-47-3 - 0.02 0.02 
Nitroso-2-oxopropylethanolamine + 92177-49-6 - 0.025 0.022 
Nitrosoheptamethyleneimine + 20917-49-1 - 0.022 0.032 
o-Aminoazotoluene - 97-56-3 - 0 0.023 
Prednisolone . 50-24-8 - 0 0 
R-(-)-2-methyl-N-nitrosopiperidine . 14026-03-0 - 0.02 0.027 
Retinol acetate . 127-47-9 - 0 0 
Trenimon . 68-76-8 - 0 0 
Triamcinolone, acetonide + 76-25-5 - 0 0 
1,2-Dichloroethane - 107-06-2 + * * 
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Carbon tetrachloride + 56-23-5 + * * 
Methylene chloride - 75-09-2 + * * 
Nitromethane + 75-52-5 + * * 
2,2-Bis(bromomethyl)-1,3-
propanediol, technical grade 
+ 3296-90-0 + 0.059 0.037 
2,4-Dinitrotoluene (containing 1.0-
1.5% 2,6-dinitrotoluene) 
. 121-14-2 + 0 0 
Acronycine - 7008-42-6 + 0 0.357 
Captafol + 2425-06-1 + 0 0 
Dibromomannitol + 488-41-5 + 0.021 0.034 
FD & C violet no. 1 - 1694-09-3 + 0.028 0.064 
Ochratoxin A -  303-47-9 + 0 0 
Phenesterin  +  3546-10-9 + 0.013 0.025 
Toluene diisocyanate, commercial 
grade (2,4 (80%)- and 2,6 (20%) 
+ 26471-62-5 
 
+ 0 0 
2,4-Diaminoanisole sulfate + 39156-41-7 + * * 
Cytembena + 16170-75-5 + * * 
Glycidol + 556-52-5 + * * 
Propane sultone + 1120-71-4 + * * 
1,2-Propylene oxide - 75-56-9 + * 0 
Acrylamide + 79-06-1 + * 0 
1,3-Butadiene - 106-99-0 + * * 
1,4-Dioxane + 123-91-1 + * * 
Acrylonitrile - 107-13-1 + * * 
Chloroprene + 126-99-8 + * * 
o-Toluidine.HCl + 636-21-5 + * * 
Vinyl chloride + 75-01-4 + * * 
Sulfallate + 95-06-7 + 0 0 
Chlorambucil + 305-03-3 + 1 0.343 
Dacarbazine  + 4342-03-4 + 0.462 0.229 
Phenacetin + 62-44-2 + * 0 
1,2,3-Trichloropropane + 96-18-4 + * * 
1,2-Dibromo-3-chloropropane + 96-12-8 + * * 
1,2-Dibromoethane + 106-93-4 + * * 
2,4-Diaminotoluene . 95-80-7 + * * 
4,4'-Sulfonylbisacetanilide . 77-46-3 + * * 
Hexamethylmelamine + ------- + * * 
4,4´-Methylene-bis(2-methylaniline) + 838-88-0 + 0 0.792 
Styrene . 100-42-5 + * 1 
2-Methoxy-3-aminodibenzofuran + 5834-17-3 + * 1 
4,4'-Methylene-bis(2-chloroaniline) + ------- + * 1 
     (table cont.)
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5-Nitro-2-furaldehyde semicarbazone + 59-87-0 + * 1 
AF-2 - 3688-53-7 + * 0.769 





+ 55738-54-0 + * 1 
5-Nitroacenaphthene + 602-87-9 + 0.846 0.923 
1-(2-Hydroxyethyl)-1-nitrosourea . 13743-07-2 + 0.914 0.93 
1-[(5-Nitrofurfurylidene)amino]-2-
imidazolidinone 
+ 555-84-0 + 0.942 0.935 
1,2-Dimethyl-5-nitroimidazole + 551-92-8 + 0.976 0.986 
1-(2-Hydroxyethyl)-nitroso-3-
ethylurea 
. ------- + 0.914 0.915 
1,3-Dibutyl-1-nitrosourea . 56654-52-5 + 0.932 0.926 
1-Allyl-1-nitrosourea . 760-56-5 + 0.909 0.963 
1-Amyl-1-nitrosourea . 10589-74-9 + 0.932 0.938 
1-Ethylnitroso-3-(2-hydroxyethyl)-
urea 
. ------- + 0.914 0.894 
1-Ethylnitroso-3-(2-oxopropyl)-urea . ------- + 0.865 0.873 
1-Nitropyrene . 5522-43-0 + 1 1 
2-(2,2-Dimethylhydrazino)-4-(5-
nitro-2-furyl)thiazole 
+ 26049-69-4 + 0.974 0.97 
2,2,2-Trifluoro-N-[4-(5-nitro-2-furyl)-
2-thiazoly]acetamide 
+ 42011-48-3 + 0.965 0.961 
2-Acetylaminofluorene + 53-96-3 + 0.951 0.948 
2-Amino-5-(5-nitro-2-furyl)-1,3,4-
oxadiazole 
. 3775-55-1 + 0.96 0.958 
2-Amino-5-(5-nitro-2-furyl)-1,3,4-
thiadiazole 
. 712-68-5 + 0.93 0.929 
2-Amino-5-nitrothiazole + 121-66-4 + 0.982 0.988 
2-Hydrazino-4-(5-nitro-2-
furyl)thiazole 
. 26049-68-3 + 0.974 0.971 
2-Hydrazino-4-(p-
aminophenyl)thiazole 
. 26049-71-8 + 0.977 0.973 
2-Hydrazino-4-(p-
nitrophenyl)thiazole 
. 26049-70-7 + 0.979 0.975 
3-(5-Nitro-2-furyl)-imidazo(1,2-
〈)pyridine 
. 75198-31-1 + 0.938 0.932 
3,3'-Dichlorobenzidine + 91-94-1 + 0.941 0.923 
3,3'-Dimethoxybenzidine.2HCl + 20325-40-0 + 0.941 0.883 
3,3'-Dimethylbenzidine.2HCl + 612-82-8 + 0.941 0.923 
3-Methylcholanthrene + 56-49-5 + 0.895 0.722 
4-(5-Nitro-2-furyl)thiazole + 53757-28-1 + 0.97 0.965 
4,6-Diamino-2-(5-nitro-2-furyl)-S-
triazine 
+ 720-69-4 + 0.955 0.953 
4,6-Dimethyl-2-(5-nitro-2-
furyl)pyrimidine 
. 59-35-8 + 0.918 0.92 
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4-Acetylaminobiphenyl . 4075-79-0 + 0.943 0.932 
4-Aminodiphenyl.HCl + 2113-61-3 + 0.941 0.931 
4-Bis(2-hydroxyethyl)amino-2-(5-
nitro-2-thienyl)quinazoline 




+ 21638-36-8 + 0.919 0.873 
Atrazine - 1912-24-9 + 1 1 
Bemitradine . 88133-11-3 + 0.949 0.949 
Benzidine + 92-87-5 + 0.941 0.923 
Carboxymethylnitrosourea - 60391-92-6 + 0.909 0.963 
Formic acid 2-(4-methyl-2-
thiazolyl)hydrazide 
. 32852-21-4 + 0.986 0.992 
Formic acid 2-[4-(5-nitro-2-furyl)-2-
thiazolyl]hydrazide 
+ 3570-75-0 + 0.968 0.965 
Hydrazobenzene + 122-66-7 + 1 1 
Indomethacin - 53-86-1 + 0.654 0.671 
IQ + 76180-96-6 + 0.979 0.987 
IQ.HCl + ------- + 0.979 0.987 




. 3031-51-4 + 0.797 0.634 
Metronidazole + 443-48-1 + 0.941 0.966 
N-[4-(5-Nitro-2-furyl)-2-
thiazolyl]acetamide 
+ 531-82-8 + 0.965 0.961 
N-(9-Oxo-2-fluorenyl)acetamide . 3096-50-2 + 0.943 0.932 
N-(N-Methyl-N-nitrosocarbamoyl)-l-
ornithine 
. 63642-17-1 + 0.892 0.752 
N-1-Diacetamidofluorene . 63019-65-8 + 0.929 0.941 
N-(2-Fluorenyl)-2,2,2-
trifluoroacetamide 
. 363-17-7 + 0.951 0.948 
N-Hexylnitrosourea + 18774-85-1 + 0.872 0.921 
N,N'-[6-(5-Nitro-2-furyl)-s-triazine-
2,4-diyl]bisacetamide 
+ 51325-35-0 + 0.917 0.918 
N-n-Butyl-N-nitrosourea + 869-01-2 + 0.932 0.938 
Nithiazide + 139-94-6 + 0.977 0.968 
PhIP.HCl + -------- + 0.953 0.948 
Trp-P-2-acetate + 72254-58-1 + 0.913 0.927 
Footnotes 
.  no Salmonella evaluation was made for the compound 
* no prediction was made for the compound 
ND: no Salmonella mutagenicity data available for compound 
Lightly shaded background: correctly predicted noncarcinogen based on optimal cut-off value 
Darkly shaded background: correctly predicted carcinogen based on optimal cut-off value 





Table 4.6 Model validation for rat mammary gland carcinogens and non-carcinogens (MC-
NC). For the ABC model, compounds with values above or equal to 37% were predicted to 
be active compounds and those below 37% were predicted to be inactive. For the ABCH 
model, compounds with values above or equal to 47% were predicted to be active and those 
below 47% were predicted as inactive. 
Model 2     
Model 3-7/0.90  













Dichlorodifluoromethane . 75-71-8 - * * 




- * * 
1-Phenyl-2-thiourea - 103-85-5 - * * 
1-Chloro-2-nitrobenzene + 88-73-3 - * * 
Acetaldoxime - 107-29-9 - * 1 
Benzaldehyde - 100-52-7 - * 0.9 
m-Toluidine hydrochloride - 638-03-9 - * 0.923 
HC blue no. 2 + 33229-34-4 - * 1 
1-Nitroso-5,6-dihydrothymine + 62641-67-2 - 0.882 0.889 
3-Hydroxy-4-acetylaminobiphenyl . 4463-22-3 - 0.97 0.925 
5-Nitro-2-furamidoxime + 772-43-0 - 0.947 0.94 
5-Nitro-2-furanmethanediol diacetate + 92-55-7 - 0.743 0.715 
Caffeine - 58-08-2 - 0.789 0.837 




- 0.949 0.943 
Norharman + 244-63-3 - 1 1 




- 0.948 0.94 
Benzylthiocyanate . 3012-37-1 - * * 
Methyl Parathion + 298-00-0 - * * 
1,1,2,2-Tetrachloroethane - 79-34-5 - * * 
N-Methylolacrylamide - 924-42-5 - * 1 
Dioxathion + 78-34-2 - * * 
Dithiooxamide . 79-40-3 - * * 
Pentaerythritol tetranitrate - 78-11-5 - * * 
p,p'-DDE - 72-55-9 - * * 
S-ethyl-L-cysteine . 2629-59-6 - * 1 
Tace - 569-57-3 - * * 
trans-Anethole . 4180-23-8 - * 0.815 
3-Nitrosomethylaminopyridine - 69658-91-9 - * 0 
Propylene + 115-07-1 - * 0 
Malathion - 121-75-5 - * 0 




- * 0 
Phenethyl isothiocyanate . 2257-09-2 - * 0.1 
Clonitralid . 1420-04-8 - * 0.077 
     (table cont.) 
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Sulfisoxazole - 127-69-5 - 0 0.816 
C.I. Pigment yellow 12 - 6358-85-6 - 0 0.63 
Ipazilide fumarate . 115436-74-3 - 0.083 0.62 
C.I. Orange 10 - 1936-15-8 - 0 0.029 
FD&C Yellow No. 6 - 2783-94-0 - 0 0.04 








- 0 0.089 
2,7-Dichlorodibenzo-p-dioxin (DCDD) - 33857-26-0 - 0 0.03 
2-Chloroacetophenone - 532-27-4 - 0 0 
2-Difluoromethylornithine . 70052-12-9 - 0 0 
4-Nitroanthranilic acid + 619-17-0 - 0.098 0.111 
5-Fluorouracil - 51-21-8 - 0 0 
6-Aminocaproic acid . 60-32-2 - 0 0.2 
alpha-Methyldopa sesquihydrate - 41372-08-1 - 0.038 0.034 
Benzyl alcohol - 100-51-6 - 0 0 
Butylated hydroxytoluene - 128-37-0 - 0 0.031 
Butyl benzyl phthalate - 85-68-7 - 0.039 0.017 
Carbromal - 77-65-6 - 0.36 0.468 
Codeine - 76-57-3 - 0.02 0.027 
Compound 50-892 . 65765-07-3 - 0 0.056 
Cyclohexanone - 108-94-1 - 0 0 
Dicofol - 115-32-2 - 0 0 
Dicyclopentadiene dioxide . 81-21-0 - 0.032 0.032 
Diphenhydramine hydrochloride - 147-24-0 - 0 0.02 
Dipyrone . 68-89-3 - 0.143 0.3 
DL-alpha-tocopheryl acetate - 58-95-7 - 0.031 0.039 
DL-Menthol - 15356-70-4 - 0.044 0.051 
Dopamine HCl + 62-31-7 - 0.044 0.038 
DL-diepoxybutane + 298-18-0 - 0 0 
Ellagic acid - 476-66-4 - 0.026 0.03 
Endosulfan - 115-29-7 - 0.038 0.044 
Endrin - 72-20-8 - 0.03 0.032 
Ephedrine sulfate - 134-72-5 - 0 0 
Erythromycin stearate - 643-22-1 - 0.022 0.028 
FD&C Red No. 3 - 16423-68-0 - 0.042 0.046 
Fenaminosulf (formulated) + 140-56-7 - 0 0 
Fenvalerate . 51630-58-1 - 0.046 0.028 
Gemfibrozil . 25812-30-0 - 0.035 0.038 
Heptylamine . 111-68-2 - 0.07 0.063 
Hexachlorocyclopentadiene (HCCPD) - 77-47-4 - 0 0 
Iodoacetamide . 144-48-9 - 0 0 
Kaempferol + 520-18-3 - 0.027 0.033 




- 0.031 0.025 




------ - 0.022 0.054 
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Orotic acid, monosodium salt . 154-85-8 - 0 0 
Oxprenolol hydrochloride . 6452-73-9 - 0.01 0.031 
Oxytetracycline hydrochloride - 2058-46-0 - 0.023 0.03 
O,S-dibenzoyl thiamine hydrochloride . 35660-60-7 - 0.14 0.424 
Picloram (technical grade) - 1918-02-1] - 0.071 0.059 
Pimaricin . 7681-93-8 - 0.012 0.017 
Piperonyl sulfoxide  - 120-62-7 - 0.044 0.036 
Probenecid - 57-66-9 - 0.091 0.07 
Propyl gallate - 121-79-9 - 0.036 0.032 
Rutin sulfate . 12768-44-4 - 0.019 0.023 
Sodium bicarbonate . 144-55-8 - 0 0 
Sotalol hydrochloride . 959-24-0 - 0.111 0.06 
Tetracycline.HCl - 64-75-5 - 0.024 0.032 
Triprolidine.HCl monohydrate -  6138-79-0 - 0.056 0.08 
Zatosetron maleate . 123482-22-4 - 0.065 0.076 
Zearalenone - 17924-92-4 - 0.055 0.041 




+ 0.034 0.175 
2,4-Diaminoanisole sulfate  39156-41-7 + * * 
4,4'-Methylene-bis(2-chloroaniline)  101-14-4 + * * 
Acronycine  7008-42-6 + 0 0 
Acrylamide  79-06-1 + * * 
Acrylonitrile  107-13-1 + * * 
Captafol  2939-80-2 + 0.021 0.027 
Carbon tetrachloride  56-23-5 + * * 
Chlorambucil  305-03-3 + 0.074 0.062 
Cytembena  16170-75-5 + 0 0 
Dibromomannitol  488-41-5 + 0.032 0.096 
FD & C violet no. 1  1694-09-3 + 0 0 
Glycidol  556-52-5 + * 0 
Isoniazid  54-85-3 + 0 0 
Methylene chloride  75-09-2 + * * 
Nitromethane  75-52-5 + * * 
Ochratoxin A  303-47-9 + 0.043 0.032 
Phenesterin   3546-10-9 + 0.012 0.022 
Procarbazine.HCl  366-70-1 + * * 
Propane sultone  1120-71-4 + * * 
Styrene  100-42-5 + * 0 
Sulfallate  95-06-7 + 0 0 
Toluene diisocyanate, commercial 
grade (2,4 (80%)- and 2,6 (20%) 
 584-84-9 
+ 0 0 
Vinyl chloride  75-01-4 + * * 
1,4-Dioxane  123-91-1 + 0 0 
1,2-Dichloroethane  107-06-2 + * * 
1,3-Butadiene  106-99-0 + * * 
Chloroprene  126-99-8 + * * 




+ 0.1 0.068 
Dacarbazine   4342-03-4 + 0 0 
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2-Methoxy-3-aminodibenzofuran  5834-17-3 + * * 
Metronidazole  443-48-1 + * * 
1,2-Dimethyl-5-nitroimidazole  551-92-8 + * * 
2,4-Dinitrotoluene (containing 1.0-
1.5% 2,6-dinitrotoluene)  
 121-14-2 
+ 0 0 
Phenacetin  62-44-2 + * 0.633 
1-Ethylnitroso-3-(2-hydroxyethyl)-urea  ------- + * 0.557 
4,4'-Sulfonylbisacetanilide  77-46-3 + * 1 
1,2,3-Trichloropropane  96-18-4 + * 1 
1,2-Dibromoethane  106-93-4 + * 1 
1,2-Dibromo-3-chloropropane  96-12-8 + * 1 
1-(2-Hydroxyethyl)-nitroso-3-ethylurea  ------- + * 0.98 
1-(2-Hydroxyethyl)-1-nitrosourea  13743-07-2 + * 0.989 
3,3'-Dimethoxybenzidine.2HCl  20325-40-0 + 0.9 0.414 





+ 0.736 0.544 
3,3'-Dichlorobenzidine  91-94-1 + 0.9 0.913 




+ 0.94 0.776 
Atrazine  1912-24-9 + 1 1 





+ 1 0.959 
1,3-Dibutyl-1-nitrosourea  56654-52-5 + 1 0.987 
1-Allyl-1-nitrosourea  760-56-5 + 0.667 0.891 
1-Amyl-1-nitrosourea  10589-74-9 + 1 0.991 
1-Ethylnitroso-3-(2-oxopropyl)-urea  110559-84-7 + 1 0.983 








+ 0.935 0.921 
2,4-Diaminotoluene  95-80-7 + 1 1 
2-Acetylaminofluorene  53-96-3 + 0.9 0.957 








+ 0.992 0.994 
2-Hydrazino-4-(5-nitro-2-furyl)thiazole  26049-68-3 + 0.994 0.995 
2-Hydrazino-4-(p-aminophenyl)thiazole  26049-71-8 + 0.986 0.988 




+ 0.994 0.995 
3,3'-Dimethylbenzidine.2HCl  612-82-8 + 0.944 0.964 




+ 1 1 
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+ 1 1 
4-Acetylaminobiphenyl  4075-79-0 + 0.9 0.957 





+ 1 0.996 
4-(5-Nitro-2-furyl)thiazole  53757-28-1 + 0.997 0.998 
5-Nitroacenaphthene  602-87-9 + 1 1 
5-Nitro-2-furaldehyde semicarbazone  59-87-0 + 1 1 
AF-2  3688-53-7 + 1 1 
Bemitradine  88133-11-3 + 0.996 0.996 
Benzidine  92-87-5 + 0.9 0.913 








+ 0.975 0.98 
Hexamethylmelamine  645-05-6 + 1 1 
IQ  76180-96-6 + 1 1 
IQ.HCl  76180-96-6 + 1 1 
Nithiazide  139-94-6 + 0.97 0.967 








+ 1 1 




+ 0.996 0.996 
o-Toluidine.HCl  636-21-5 + 1 1 







+ 1 1 
Trp-P-2-acetate  72254-58-1 + 0.778 0.914 













Table 4.7 Model validation for mouse mammary gland carcinogens and non-mammary gland 
carcinogens (MC-NMC). For the ABC 3/0.75 model, compounds with values equal to or 
above 76% were predicted to be active compounds and those below 76% were predicted to 
be inactive. For the ABCH 3/0.90, ABC 3/0.90 and ABCH 3/0.75 models, the optimal cut-off 
values were 62%, 95% and 76%, respectively. 








Chemical      CASN Experimental 
Activity 
% Active 
 (0.95)  
% Active  
(0.62) 
% Active 
 (0.76)  
% Active 
 (0.76) 
Cyclamate sodium 100-88-9 - * 1 0.808 0.853 
Daminozide 1596-84-5 - 1 1 1 0.934 
Dichloroacetylene 7572-29-4 - * * * * 
Isoprene 78-79-5 - 1 0.985 0.95 0.921 
Trichloroaceticacid 76-03-9 - * * * * 
Tris(2,3-dibromopropyl) phosphate 126-72-7 - 0.944 0.98 0.944 0.896 
Ethylhydrazine.HCl 18413-14-4 - * * 0.75 0.762 
1,1,2,2-Tetrachloroethane 79-34-5 - * * 0.25 0.227 
1,2-Dichloropropane 78-87-5 - * 1 0.25 0.67 
alpha-1,2,3,4,5,6-
Hexachlorocyclohexane-d6 
86194-41-4 - * * 0.731 0.757 
1'-Hydroxysafrole 5208-87-7 - * 0.618 0.228 0.33 
3-Methoxy-4-aminoazobenzene 3544-23-8 - * 0.265 0.182 0.207 
3-(Chloromethyl) pyridine 
hydrochloride 6959-48-4 - * 0.333 0.244 0.209 
4-Chloro-4'-aminodiphenylether 101-79-1 - * 0.1 0.182 0.176 
4-Chloro-m-phenylenediamine 5131-60-2 - * 0.1 0.182 0.169 
Benzyl chloride 100-44-7 - * 0 0.178 0.181 
m-Toluidine.HCl 638-03-9 - * 0.077 0.18 0.173 
p,p'-DDD 72-54-8 - * 0 0.182 0.183 
2-Acetylaminofluorene 53-96-3 - 0 0.059 0.183 0.183 
2-Hydrazino-4-(p-
aminophenyl)thiazole 26049-71-8 - 0 0.059 0.187 0.177 
3,3',4,4'-Tetraaminobiphenyl 
tetrahydrochloride 
7411-49-6 - 0 0.059 0.185 0.179 
3,3'-Dimethylbenzidine 
dihydrochloride 612-82-8 - 0 0.059 0.183 0.181 
Benzidine.2HCl 531-85-1 - 0 0.059 0.185 0.178 
Phenacetin 62-44-2 - 0.9 0.486 0.232 0.274 
1,2-Dibromoethane 106-93-4 + * * * * 
1,2-Dichloroethane 107-06-2 + 0 0 0 0 
Benzene 71-43-2 + * * * * 
C.I. Direct black 38 1937-37-7 + 0.046 0.057 0.046 0.059 
Furosemide 54-31-9 + 0.426 0.289 0.372 0.257 
Nitrobenzene 98-95-3 + * * * * 
Estradiol 50-28-2 + 0.551 0.681 0.524 0.608 
      (table cont.) 
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Vinyl fluoride 75-02-5 + * * * 0.769 
1,3-Butadiene 106-99-0 + * * 0.8 0.78 
5-Azacytidine 320-67-2 + 1 1 0.955 0.943 
α-Ecdysone 3604-87-3 + 1 1 0.96 0.949 
Calciferol 50-14-6 + 1 1 0.948 0.931 
Chloroprene 126-99-8 + 1 1 0.875 0.82 
Diethylstilbestrol 56-53-1 + 1 1 0.986 0.976 
Ethylene oxide 75-21-8 + 1 1 0.857 0.844 
Glycidol 556-52-5 + 1 1 0.929 0.939 
Griseofulvin 126-07-8 + 1 0.987 0.77 0.808 
Isoniazid 54-85-3 + 1 0.975 1 0.888 
Isonicotinic acid 
vanillylidenehydrazide 149-17-7 + 1 1 1 0.928 
(N-6)-(Methylnitroso)adenosine ------ + 1 1 0.947 0.964 
Reserpine 50-55-5 + 1 1 0.95 0.926 
Sulfallate 95-06-7 + 1 1 1 0.829 
Vinylidene chloride 75-35-4 + 1 1 1 0.829 
Vinyl chloride 75-01-4 + 1 1 1 0.829 
Footnotes: See Table 4.5 
 
Table 4.8 Model validation for mouse mammary gland carcinogens and rodent non-
carcinogens (MC-RNC). For the ABC 3/0.75 model, compounds with values equal to or 
greater than 30% were predicted  to be active compounds and those below 30% were 
predicted to be inactive. For the ABCH 3/0.90, ABC 3/0.90, and ABCH 3/0.75 models, these 
optimal cut-off values were 93%, 1% and 42%, respectively. 
Model 1  
 








Chemical CASN Experimental 
Activity 
% Active 
 (0.01)  
% Active  
(0.93) 
% Active 





71-55-6 - * * * * 
3-Sulfolene 77-79-2 - * * * 0.8 
Benzoguanamine 91-76-9 - * * * * 
Cyanamide, calcium 156-62-7 - * * * * 
Dichlorodifluoromethane 75-71-8  - * * * * 
Hexamethylenetetramine 100-97-0 - * * * * 
Octachlorostyrene 29082-74-4 - 1 1 1 1 
Propylene 115-07-1 - * 1 * 0.875 
Saccharin 81-07-2 - 1 1 0.78 0.857 
Deltamethrin 52918-63-5 - 1 0.919 0.459 0.556 
Gemfibrozil 25812-30-0 - 1 0.925 0.534 0.659 
Hydrochlorothiazide 58-93-5 - * * 0.25 0.25 
Pyrazinamide 98-96-4 - * * 0.25 0.412 
Urea 57-13-6 - * * 0.25 0.25 




1095-90-5 - * 0 0.176 0.291 
Dimethylformamide 68-12-2 - * 0 0.222 0.167 
Methoxychlor 72-43-5 - * 0 0.298 0.294 
Omeprazole 73590-58-6 - 1 0.167 0.234 0.284 
Oxamyl 23135-22-0 - * 0 0.222 0.167 
Tolbutamide 64-77-7 - * 0 0.188 0.21 
Caffeine 58-08-2 - 0 0 0.163 0.156 
Diazepam 439-14-5 - 0 0 0.163 0.221 
Nefiracetam 77191-36-7 - 0 0.108 0.168 0.274 
Prazepam 2955-38-6 - 0 0.526 0.163 0.414 
1,2-Dibromoethane 106-93-4 + * * * * 
1,2-Dichloroethane 107-06-2 + * * * * 
Benzene 71-43-2 + * * * * 
Nitrobenzene 98-95-3 + * * * * 
Furosemide 54-31-9 + 0 0 0.165 0.146 
Sulfallate 95-06-7 + 0 0.176 0.24 0.268 
Vinyl fluoride 75-02-5 + * * * 0.833 
Isoniazid 54-85-3 + * * 0.429 0.465 
C.I. Direct black 38 1937-37-7 + * 1 0.221 0.265 
Vinylidene chloride 75-35-4 + * 1 0.75 0.875 
Vinyl chloride 75-01-4 + * 1 0.75 0.857 
Estradiol 50-28-2 + 0.442 0.617 0.484 0.6 
Griseofulvin 126-07-8 + 0.432 0.569 0.447 0.577 
5-Azacytidine 320-67-2 + 0.719 0.869 0.615 0.794 
1,3-Butadiene 106-99-0 + 1 1 1 0.9 
α-Ecdysone 3604-87-3 + 1 0.988 0.865 0.893 
Calciferol 50-14-6 + 1 0.966 0.924 0.888 
Chloroprene 126-99-8 + 1 1 0.875 0.9 
Diethylstilbestrol 56-53-1 + 1 1 0.923 0.848 
Ethylene oxide 75-21-8 + 1 1 0.923 0.9 
Glycidol 556-52-5 + 1 1 0.951 0.954 
Isonicotinic acid 
vanillylidenehydrazide 
149-17-7 + 1 1 0.508 0.522 
(N-6)-(Methylnitroso) adenosine ------ + 1 0.987 0.887 0.913 
Reserpine 50-55-5 + 1 0.964 0.787 0.781 
Footnotes: See Table 4.5 
 
4.1.3 Predictive Performance of cat-SAR CPDB Rodent Models  
The models assessed for predictivity were the general rat and mouse, and female-
specific rodent ABC and ABCH models. During LOO-CV the sensitivity, specificity, and 
concordance values of the models were established. Through LOO-CV, both rodent and 
female-specific models produced results in favor of the ABC 90% requirement. The rat 
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model attained a sensitivity of 70% and a specificity of 69% yielding a concordance of 70% 
(ABC 3/0.90, Table 4.9). Predictions were made on 459 of the chemicals in the learning set. 
This learning set was comprised of a total of 946 chemicals. Therefore, the model made 
predictions on about half (i.e., 49%) of the test compounds. Likewise, the general mouse 
model was able to achieve a concordance between experimental and predicted results of 70% 
with a sensitivity of 74% and a specificity of 67% (ABC 3/0.90, Table 4.10).  For this model, 
predictions were made on 346 of the 769 chemicals in the learning set. Again, the model was 
able to predict about half (i.e., 45%) of the test compounds in the dataset.  
Table 4.9 Predictive performance of the general CPDB rat carcinogen model with 3 to 7 
heavy atoms. 
 
Model                Total          Model          Active         Inactive        Sensitivity          Specificity             OCP  
(opt. 0.27)         Fragments  Fragments   Fragments   Fragments                                                             
ABC 3/0.75 41886 5026 2450 2576 0.61(235/386) 0.74(257/349) 0.67(492/735) 
        
ABC 3/0.90 41886 3400 1773 1627 0.70(171/243) 0.69(148/216) 0.70(319/459) 
        
ABCH 3/0.75 89509 11716 5496 6220 0.62(267/434) 0.73(290/398) 0.67(557/832) 
        
ABCH 3/0.90 89509 7594 3885 3709 0.63(199/317) 0.73(213/292) 0.68(412/609) 
        
Footnotes: See Table 4.1 
Table 4.10 Predictive performance of the general CPDB mouse carcinogen model with 3 to 7 
heavy atoms. 
















    OCP  
 
  
ABC 3/0.75 33560 4070 1282 2788 0.60(177/293) 0.72(207/289) 0.66(384/582)
        
ABC 3/0.90 33560 2428 919 1509 0.74(121/163) 0.67(122/183) 0.70(243/346)
        
ABCH 3/0.75 70076 10070 3268 6802 0.69(237/342) 0.60(207/348) 0.64(444/690)
        
ABCH 3/0.90 70076 6027 2369 3658 0.66(159/242) 0.73(175/241) 0.69(334/483) 
        
Footnotes: See Table 4.1 
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Analysis of the female-specific rodent datasets also provided findings reflective of the 
model’s consistency. Taking into consideration that these two models were subsets of the 
general rodent models, it was expected that the predictive performance of these models 
would be similar to that of the general rodent models. The best female rat model achieved a 
sensitivity of 61% and a specificity of 73% yielding an OCP of 67% (ABC 3/0.90, Table 
4.11). This learning set was comprised of 723 chemicals and the model made predictions on 
357 test compounds.  Therefore, the model made predictions on approximately 49% of the 
compounds in the learning set. Lastly, the best female mouse model had an OCP of 73% with 
a sensitivity of 61%, and a specificity of 83% (ABC 3/0.90, Table 4.12). This model made 
predictions on 371 of its 738 test compounds (i.e., 50% of all chemicals comprising the 
model).  
Table 4.11 Predictive performance of the CPDB female rat carcinogen model with 3 to 7 
heavy atoms and 75% and 90% optimal cut-offs of 0.26 and 0.32, respectively. 
 
Model                Total        Model          Active         Inactive           Sensitivity          Specificity           OCP 
(opt. 0.32)       Fragments  Fragments   Fragments   Fragments                                                           
ABC 3/0.75 36131 3793 1500 2293 0.69(203/293) 0.64(171/269) 0.67(374/562)
        
ABC 3/0.90 36131 2557 1062 1495 0.61(108/176) 0.73(132/181) 0.67(240/357)
         
Footnotes: See Table 4.1 
Table 4.12 Predictive performance of the CPDB female mouse carcinogen model with 3 to 7 
heavy atoms and 75% and 90% optimal cut-offs of 0.48 and 0.51, respectively. 
 
Model                Total        Model        Active         Inactive         Sensitivity            Specificity              OCP 
(opt. 0.51)       Fragments  Fragments  Fragments  Fragments                                                           
ABC 3/0.75 32925 3339 1076 2263 0.60(140/234) 0.72(234/290) 0.71(374/524) 
        
ABC 3/0.90 32925 2617 804 1813 0.61(102/167) 0.83(169/204) 0.73(271/371) 
         
Footnotes: See Table 4.1 
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4.1.4 Analysis of the General Rodent Models 
Of importance, all four mammary and female-specific learning sets were subsets of 
the CPDB general rat and mouse learning sets. Model consistency in terms of OCP values 
was observed among ABC and ABCH models. It was also noted that the 75% models made 
predictions on a greater number of test compounds as previously seen with the mammary 
carcinogen models. For example, when comparing the 75% and 90% proportions for the rat 
dataset, the ABC 75% model made predictions on 735 chemicals in the dataset, whereas the 
ABC 90% model made predictions on 459 test chemicals in the dataset (Table 4.10). In other 
words, the rat ABC 75% model was able to make predictions on 78% of the 946 chemicals in 
the learning set compared to 49% by the ABC 90% model. 
The best model produced for the mouse-female dataset was from the ABC 90% 
criterion. It is important to note that although this model produced a high predictivity, it was 
not the more inclusive model in comparison to the ABC 75% (Table 4.9). However, for the 
rat female dataset, the most predictive model was that of the ABC 75% criterion. This model 
was chosen for its predictive capacity to correctly predict a great number of active and 
inactive chemicals.  Again, when comparing the ABC and ABCH models it was observed 
that the ABCH increased ability to make predictions on a large number of chemicals did not 
improve the model’s OCP value. Instead, the model’s accuracy remained almost stable and in 
some cases the OCP was slightly reduced. 
To judge the predictive performance of the cat-SAR system, the NTP Salmonella 
mutagenicity database, and an analysis of the CPDB by Gold and collaborators were 
considered as ‘gold-standards’. The rodent results were also compared to that of a separate 
study published on organ-specific carcinogenic databases by Young and others (Young et al 
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2004). Young et al. SAR analyses based on chemicophysical parameters for validating rodent 
carcinogens, the model was at best 30% sensitive and 77% specific (Young et al 2004). This 
uneven distribution of correct active and inactive predictions appears to be a common trend 
seen in current SAR approaches. However, balanced sensitivity and specificity percent 
values as presented in the previous tables (Table 4.9-4.12) are characteristic of the cat-SAR 
models.  
Another published CPDB rat and mouse SAR study using the CASE/MULTICASE 
(MCASE) expert system by Cunningham et al. achieved concordances similar to that of the 
cat-SAR rat and mouse models.  In a 10-fold cross-validation study where 10 disjoint sets of 
10% of the chemicals were removed from the rat database and the remaining 90% of the 
chemicals were used as a learning set, MCASE was able to achieve a concordance between 
experimental and predicted results of 64% (Cunningham et al 1998). The model’s sensitivity 
and specificity values were 55% and 73%, respectively. However, when Cunningham et al. 
applied a modified validation process (i.e., removal of all chemicals that were identified by a 
‘unique’ structural alert were removed from consideration) designed to investigate the 
predictivity of a more focused rat SAR model, MCASE achieved a concordance of 71% 
(Cunningham et al 1998). In light of the model’s respectable OCP value, the model’s 
sensitivity and specificity values attained were 69% and 73%, respectively. In a similar 
MCASE study designed to identify genotoxic and non-genotoxic alerts for cancer in mice 
using the CPDB data, a concordance of 70% with a sensitivity of 63% and a specificity of 
78% was achieved through LOO-CV. These values are close to the overall rat and mouse 
concordances derived from the cat-SAR study and indicate that the cat-SAR and MCASE 
systems are performing similarly.  
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Furthermore, Gold et al. stated that in ‘near replicate’ (i.e., cancer bioassay repeated 
with the same chemical) comparisons of rat cancer bioassays a reproducibility of 85% is 
estimated while mouse bioassays are estimated to be 80% reproducible (Gold 1987). The 
Salmonella mammalian microsome mutagenicity (Ames) test was designed to measure 
mutations using several strains of the Salmonella typhimurium (Ames et al 1973). As stated, 
the interlaboratory reproducibility of the Salmonella assay is 85% (Zeiger 1985). The cat-
SAR system achieved an estimated 80% concordance for the Salmonella mutagenicity assay 
(data not shown). Taking into consideration the complexity of the endpoint (i.e., mechanisms 
of carcinogenesis), the cat-SAR system can usefully complement the results of the rodent 
bioassay and short-term tests.  
4.1.5 Training/Test Set: Respiratory Sensitization cat-SAR Study 
The cat-SAR method has been employed successfully in validating and predicting the 
biological activity of human respiratory chemical sensitizers (Cunningham et al; in press 
2005).  This group of compounds served as a test set in developing the cat-SAR method and 
have been accepted for publication. Once again, in comparison to results attained from other 
SAR approaches, the respiratory sensitization cat-SAR models were very successful in terms 
of its sensitivity, specificity, and OCP (Table 4.13). These analyses also illustrate that cat-
SAR is applicable to diverse biological endpoints and that the predictive performance of the 
rodent and mammary-specific carcinogenicity models was not attained by chance. It should 
be noted that it is speculated that the respiratory sensitization ABC and ABCH models 





Table 4.13 Predictive performance of ABC and ABCH respiratory sensitization models 
based on fragments of size between three and seven heavy atoms and considered atoms, 
bonds, and atom connection. The ABCH model also included consideration of hydrogen 









Sensitivity  Specificity  OCP  
        
ABC  5737 1305 1213 92 0.94 0.87 0.91 
ABCH  14424 3356 2926 430 0.89 0.95 0.92 






























































Figure 4.1 Illustration of the 22 significant fragments contributing to the active validation 














Figure 4.2 Illustration of the eight significant fragments contributing to the inactive 
validation prediction of the non-sensitizer 2,4-dimethylbenzyl acetate. 
 
4.1.6 Identifying Structural Alerts 
The chemical fragments illustrated in the preceding figures were chosen for two 
reasons: (1) it was feasible to select chemicals with few significant fragments as some 
compounds generated hundreds of key features contributing to its prediction. This made it 
more practical for clear illustration; and (2) by using the compounds whose mechanisms are 
already well documented and understood in the literature made it possible to verify that the 
models were mechanistically sound. Ashby et al established a group of structural alerts 
described on the basis of their inherent electrophilicity or electrophilic metabolites for DNA 
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reactivity and cancer (Ashby and Paton, 1993). These structural alerts for carcinogens, as 
described by Ashby, were used as a guide in explaining the cat-SAR system’s basis for 
identifying mechanistically justifiable structural features of genotoxic and non-genotoxic 
carcinogens (i.e., aromatic amines, nitrogen mustards, epoxides). 
It is important to note that the chemical predictions being made are solely dependent 
upon results of the LOO-CV procedure. As discussed, each removed chemical is predicted 
based on the significant fragments of the model’s remaining chemicals. Hence, the chemicals 
own fragments are not contributive to its active or inactive prediction.  
 4.1.6.1 1-Phenyl-3,3-dimethyltriazene (PDMT) 
1-Phenyl-3,3-dimethyltriazene (PDMT) was selected to demonstrate cat-SAR 
predictions of non-mammary carcinogens based on the rat MC-NMC model. PDMT is an 
alkylating agent with strong antimutagenic effects of fluoride on its mutation induction in 
Drosophila melanogaster (Vogel 1973). This compound is the most well known triazene 
used in anticancer studies. The formation of O6-methyldeoxyguanosine (O6-MedG) by 
PDMT in DNA and O6-alkylguanine-DNA alkyltransferase (ATase) in human peripheral 
leukocytes has been observed (Lee et al 1994). This compound has not been tested in mice. 
However, based on its classification in the CPDB, PDMT has been shown to induce cancer 
of the nervous system. 
This Salmonella mutagen was correctly predicted by the cat-SAR program as an 
inactive compound in terms of its inability to induce mammary gland tumors in rats. PDMT 
was shown to have a 98% probability of being a non-mammary carcinogen (Table 4.14). 
Based upon the eight structural alerts shown to be responsible for the non-induction of 
mammary tumors in the rat by the cat-SAR program, PDMT’s inactivity appear to be due in 
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large to the N-N=N chemical group extending from the phenyl ring (Figure 4.3).  The 
depicted fragments (with the exception of fragment 1552) were all derived from other rat 
non-mammary carcinogens.  
Table 4.14 Fragments from the ABC model leave-one-out validation analysis used to predict 
the inactivity of the rat non-mammary gland carcinogen 1-phenyl-3,3-dimethyltriazene. 
  
Fragment No. Active No. Inactive Total % Active % Inactive 
      
Frag1552 1 11 12 0.083 0.917 
Frag1557 0 5 5 0.000 1.000 
Frag1558 0 5 5 0.000 1.000 
Frag1559 0 5 5 0.000 1.000 
Frag1561 0 5 5 0.000 1.000 
Frag1572 0 6 6 0.000 1.000 
Frag1576 0 6 6 0.000 1.000 
Frag1577 0 5 5 0.000 1.000 
 































Figure 4.3 Illustration of the 8 significant fragments contributing to the inactive validation 
prediction of the rat non-mammary carcinogen 1-phenyl-3,3-dimethyltriazene. 
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  4.1.6.2 Nithiazide 
 
 Nithiazide was selected to illustrate cat-SAR prediction of mammary carcinogens 
based on the rat MC-NMC model. This chemical agent is a synthetic antiprotozoal agent 
used in poultry farming. Though epidemiological studies have provided "sufficient" evidence 
of nithiazide’s carcinogenicity in humans, the carcinogenicity tests in male and female rats 
and mice are considered to be inconclusive because of limitations in the design and results of 
these tests (IARC, 1981, 1987). Humans may be exposed as a result of its manufacture and 
use in veterinary medicine. Nithiazide has been tested for carcinogenicity in one experiment 
in mice and in one experiment in rats by administration in the diet. It increased the incidence 
of hepatocellular carcinomas and adenomas in male mice. Additionally, nithiazide does not 
induce mammary tumors in male rats. In female rats, it increased the incidences of 
fibroadenomas and cystadenomas of the skin, subcutaneous tissue and mammary gland and 
the incidence of endometrial stromal polyps of the uterus.  
The 29 structural alerts responsible for the mammary carcinogenicity of the chemical 
nithiazide were identified (Figure 4.4). Of interest, the genotoxic nitro (NO2) component was 
excluded from the depiction of structural features identified to be responsible for the 
induction of mammary tumorigenesis. Although, this chemical group is considered a 
structural alert for carcinogenicity (mutagenicity) when examining cancer in the general 
rodent data it is not significant according to this study in terms of breast cancer induction. 
The analyses suggest that this genotoxic chemical elicits breast carcinogenic effects due to 
the presence of the molecular fragments shown in Figure 4.2. In particular, fragments of the 
C2-S-C ring structure and S-C-N group appear to contribute heavily to the breast 
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carcinogenic action of nithiazide. The finding was based on the presence of these groups in 
several other mammary gland carcinogens in the model. 
There are several reasons to possibly assess the exclusion of the nitro (-NO2
-) 
component based on the findings of the cat-SAR program: (1) the nitro component may not 
be associated with mammary carcinogenicity, (2) this structural feature may not discriminate 
carcinogens from non-carcinogens, and/or (3) this fragment may have not met the set criteria 
and as a result was eliminated from the final model. More than likely, it is speculated that the 
third reason may be the most concise. It is possible that this genotoxic structural alert to 
carcinogenicity was found in both general carcinogens and breast carcinogens. In other 
words, the nitro component was present on both sides of the MC-NMC model. Thus, it would 
be ruled out based on the user criterion governing structural features found equally in active 
and inactive compounds. With respect to the first possible explanation, it is very unlikely that 
the NO2 electrophile is not a structural alert to mammary cancer considering a lot of nitro-
containing chemicals have been identified to be mammary carcinogens (i.e., contain the 
genotoxic nitro group that binds to macromolecular structures such as DNA). Studies have 
been conducted that demonstrate nitro-mediated mammary tumorigenesis (Jadeski et al 
2003). Thus, providing reason to believe that nitro activity is positively associated with 
breast cancer progression. Jadeski et al. demonstrated specifically how chemicals that serve 
as nitro donors stimulate phosphorylation of extracellular signal-regulated kinases (ERK), 
demonstrating a role for endogenous and exogenous nitro groups in ERK activation (Jadeski 
et al 2003).  
The genotoxic chemical nithiazide was predicted to be a rat mammary gland 
carcinogen based on 29 structural alerts found predominately in mammary carcinogens 
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(Figure 4.4). Six of the 29 fragments also included some inactive components. This 
contributed to the compound having a 97.7% probability of being a rat mammary gland 
carcinogen (Table 4.15). 
Table 4.15 Fragments from the ABC model leave-one-out validation analysis used to predict 
the activity of the rat mammary gland carcinogen nithiazide. 
  
Fragment   No. Active No. Inactive Total % Active % Inactive 
      
Frag328   11 1 12 0.917 0.083 
Frag352   11 1 12 0.917 0.083 
Frag361 12 1 13 0.923 0.077 
Frag508 21 2 23 0.913 0.087 
Frag746 12 1 13 0.923 0.077 
Frag756  12 1 13 0.923 0.077 
Frag1739 10 0 10 1.000 0.000 
Frag1740 10 0 10 1.000 0.000 
Frag1741 10 0 10 1.000 0.000 
Frag1742 9 0 9 1.000 0.000 
Frag1743 9 0 9 1.000 0.000 
Frag1744  9 0 9 1.000 0.000 
Frag1745 9 0 9 1.000 0.000 
Frag1746  9 0 9 1.000 0.000 
Frag1747 9 0 9 1.000 0.000 
Frag1754 9 0 9 1.000 0.000 
Frag1758 10 0 10 1.000 0.000 
Frag1759 9 0 9 1.000 0.000 
Frag1765 10 0 10 1.000 0.000 
Frag1775  11 0 11 1.000 0.000 







































































































































































Figure 4.4 Illustration of the 29 significant fragments contributing to the active validation 







Formulated fenaminosulf was selected to illustrate the cat-SAR program’s utility in 
distinguishing rat noncarcinogens from mammary carcinogens based on the rat MC-NC 
model. Fenaminosulf (p-dimethylaminobenzenediazo sodium sulfonate), an active ingredient 
in several commercial fungicides, was reported to be mutagenic in Salmonella typhimurium 
(McCann et al 1975). Since fenaminosulf has structural similarity to the potent carcinogen, 
butter yellow (p-dimethylaminoazobenzene), it has been evaluated for possible mutagenicity 
in Drosphila melanogaster (Pai 1983) and also for its carcinogenic potential in the rodent 
bioassay (NTP 1978).  No statistically significant positive associations were demonstrated. 
There are conflicting reports concerning this compound’s ability to induce hepatomas in rats. 
However, based on this aromatic diazo compound’s classification in the CPDB, fenaminosulf 
does not induce cancer in male and female rats and mice.  
The cat-SAR program identified seven fragments responsible for the deactivation of 
formulated fenaminosulf in rats resulting in an inactive prediction being made for the 
compound (Table 4.15). Each of the seven fragments was observed in a total of four other 
compounds in the dataset. All four of these chemicals were non-mammary carcinogens.  
Table 4.16 Fragments from the ABC 3/0.90 model leave-one-out validation analysis used to 
predict the inactivity of the rat noncarcinogen fenaminosulf. 
  
Fragment No. Active No. Inactive Total % Active % Inactive 
      
Frag 6443 0 4 4 0.000 1.000 
Frag 6446 0 4 4 0.000 1.000 
Frag 6447 0 4 4 0.000 1.000 
Frag 6451 0 4 4 0.000 1.000 
Frag 6452 0 4 4 0.000 1.000 
Frag 6455 0 4 4 0.000 1.000 
Frag 6461 0 4 4 0.000 1.000 
      




























Figure 4.5 Illustration of the 7 significant fragments contributing to the inactive validation 




Atrazine (ATR) was selected to illustrate cat-SAR’s potential to predict mammary 
carcinogens based on the rat MC-NC model. Atrazine was one of the very few male-only 
mammary carcinogens in the MC-NC learning set. ATR does not induce tumors at any other 
site in the male rat. According to atrazine’s classification in the CPDB, ATR has been shown 
to induce tumors in the hematopoietic system and also the uterus in female rats. Hazard 
assessment of the widely used chloro-S-triazine herbicide, atrazine, has largely focused on 
the compound’s induction of mammary tumors. ATR is not estrogenic and most studies have 
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found that it is not mutagenic in Salmonella typhimurium (Brusick 1994). Atrazine has been 
tested for mutagenic potential in more than 50 studies of gene mutation, chromosomal 
aberration, and primary DNA damage, and a weight-of-evidence evaluation indicates a 
nonmutagenic status relative to conventional health effects-testing formats (Brusick 1994).  
Atrazine is metabolized in mammals principally by dealkylation of the amino groups 
(Eldridge et al 1994). Studies in humans have shown that metabolism proceeds in much the 
same manner as in rodents (Adams et al 1990), However, one might surmise that the rat 
model is more sensitive than other species, including humans, to hormone-related effects 
because metabolism and clearance in rats proceed at a slower rate (Eldridge et al 1994). 
ATR was correctly predicted to be a rat mammary carcinogen based on ten fragments 
(Figure 4.6). All ten structural alerts identified were also present in three other mammary 
carcinogens. ATR was predicted to have a 100% probability of being a mammary carcinogen 
in rats (Table 4.16).  
Table 4.17 Fragments from the ABC 3/0.90 model leave-one-out validation analysis used to 
predict the activity of the rat mammary gland carcinogen atrazine. 
  
Fragment   No. Active No. Inactive Total % Active % Inactive 
      
Frag 3662   3 0 3 1.000 0.000 
Frag 3663  3 0 3 1.000 0.000 
Frag 3664 3 0 3 1.000 0.000 
Frag 3665 3 0 3 1.000 0.000 
Frag 3666 3 0 3 1.000 0.000 
Frag 3667 3 0 3 1.000 0.000 
Frag 3668 3 0 3 1.000 0.000 
Frag 3670 3 0 3 1.000 0.000 
Frag 3671 3 0 3 1.000 0.000 
Frag 3677 3 0 3 1.000 0.000 
 





























































Figure 4.6 Illustration of the 10 significant fragments contributing to the active validation 




Diazepam was selected to illustrate cat-SAR prediction of mouse non-mammary 
carcinogens based on the mouse MC-RNC model. Epidemiological studies have found no 
positive relation with breast cancer risk or with the extent of disease and lymph node 
involvement, and the possibility of a protective effect has been suggested (Kleinerman et al 
1984). Additionally, diazepam has been evaluated in Salmonella and found to be non-
mutagenic. 
Diazepam was predicted by cat-SAR to be a mouse non-mammary carcinogen. 
Diazepam has been tested in both male and female rats and mice and has not been observed 
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to induce cancer in any of the four groups. Each of the eight fragments were predominately 
found in other non-mammary carcinogens (Table 4.17 and Figure 4.7). However, 4 of the 
eight fragments included inactive features. As such, diazepam was predicted to have an 84% 
probability of being a mouse non-mammary carcinogen.  
Table 4.18 Fragments from the ABC 3/0.75 model leave-one-out validation analysis used to 
predict the inactivity of the rodent non-carcinogen diazepam. 
  
Fragment No. Active No. Inactive Total % Active % Inactive 
      
Frag188 3 9 12 0.250 0.750 
Frag201 1 6 7 0.143 0.857 
Frag238 2 6 8 0.250 0.750 
Frag1340 1 3 4 0.250 0.750 
Frag1346 0 3 3 0.000 1.000 
Frag1351 0 3 3 0.000 1.000 









































Figure 4.7 Illustration of the 8 significant fragments contributing to the inactive validation 




Calciferol (i.e., vitamin D) was selected to illustrate cat-SAR prediction of mouse 
mammary carcinogens based on the mouse MC-RNC model. Calciferol has only been tested 
in mice and has not been shown to induce tumors at any other site. Calciferol was correctly 
predicted to be a mouse mammary carcinogen based on the possession of 23 significant 
fragments (Figure 4.8). All 23 fragments were predominately found in mammary 
carcinogens. However, 7 of the 23 structural alerts also included some inactive features 
(Table 4.18). As such, calciferol was predicted to have a 92.4% probability of being a mouse 
mammary carcinogen. There is no Salmonella mutagenicity data for this compound. 
Table 4.19 Fragments from the ABC 3/0.75 model leave-one-out validation analysis used to 
predict the activity of the mouse mammary gland carcinogen calciferol. 
  
Fragment   No. Active No. Inactive Total % Active % Inactive 
      
Frag9   4 0 4 1.000 0.000 
Frag333   8 1 9 0.889 0.111 
Frag372 7 1 8 0.875 0.125 
Frag382 6 0 6 1.000 0.000 
Frag383 5 0 5 1.000 0.000 
Frag388  4 1 5 0.800 0.200 
Frag638 3 0 3 1.000 0.000 
Frag640 3 0 3 1.000 0.000 
Frag641 3 0 3 1.000 0.000 
Frag642 3 0 3 1.000 0.000 
Frag652 3 1 4 0.750 0.250 
Frag653 3 0 3 1.000 0.000 
Frag679 3 0 3 1.000 0.000 
Frag680  3 0 3 1.000 0.000 
Frag682 3 0 3 1.000 0.000 
Frag685 3 0 3 1.000 0.000 
Frag702 3 0 3 1.000 0.000 
Frag750 3 1 4 0.750 0.250 
Frag796 3 1 4 0.750 0.250 
Frag846  3 1 4 0.750 0.250 























































Figure 4.8 Illustration of the 23 significant fragments contributing to the active validation 






1’-Hydroxysafrole was selected to illustrate the cat-SAR program’s prediction of 
mammary carcinogens based on the mouse MC-NMC model. Based on its classification in 
the CPDB, 1’-hydroxysafrole has been tested in male and female mice and male rats. 1’-
Hydroxysafrole is a proximate carcinogenic metabolite of the naturally occurring 
hepatocarcinogen safrole. The sulfuric acid ester of 1’-hydroxysafrole, namely 1’-
sulfoxysafrole, was shown to be the major ultimate electrophilic and carcinogenic metabolite 
of 1’-hydroxysafrole in mouse liver (Miller et al 1983). The sulfuric acid ester of 3’-
hydroxyisosafrole was also shown to be electrophilic when chemically synthesized or 
generated enzymatically in vitro (Miller et al 1983). However, no evidence has been obtained 
for in vivo metabolism of 3’-hydroxyisosafrole to a sulfuric acid ester in the mouse.  
In one study, administration of 1’-hydroxysafrole to mice in the diet for 4-14 days 
caused a 90% inhibition of the covalent binding of a subsequent dose of 1’-hydroxysafrole to 
the hepatic macromolecules (Miller 1983). This effect was due to increased detoxification of 
1’-hydroxysafrole rather than to an inhibition of metabolic activation. Under the test 
conditions, 1’-hydroxysafrole had very little, if any, tumor-initiating activity in rat liver, but 
did exhibit strong promoting activity. This promoting activity was inhibited almost 
completely by pentachlorophenol, indicating that it was mediated by the electrophilic sulfuric 
acid ester of 1’-hydroxysafrole (Miller et al 1983). 
Sulfation is a common final step in the biotransformation of xenobiotics and is 
traditionally associated with inactivation. However, the sulfate group is electron withdrawing 
and may be cleaved off heterolytically in some molecules leading to electrophilic cations 
which may form adducts with DNA and other important cellular structures (Glatt 1998). 
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Since endogenous sulfotransferases do not appear to be expressed in indicator cells of 
standard mutagenicity tests, rat and human sulfotransferases have been stably expressed in 
his-Salmonella typhimurium strain TA1538 and Chinese hamster V79 cells by Glatt and 
collaborators. Using these recombinant indicator cells, sulfotransferase-dependent genotoxic 
activities were detected with 1’-hydroxysafrole (Glatt 1998). In other cases, spontaneous 
benzylic substitution reactions with medium components, such as halogenide ions or amino 
acids, led to secondary, membrane-penetrating reactive species.  
Different sulfotransferases, including related forms from rat and human, substantially 
differed in their substrate specificity towards the investigated promutagens. It is known that 
some sulfotransferases are expressed with high tissue and cell type specificities (Glatt 1998). 
As described by Glatt, this site-dependent expression together with the limitations in the 
distribution of reactive sulfuric acid conjugates may explain organotropic effects of 
compounds activated by this metabolic pathway (Glatt 1998). 
Herein, the cat-SAR program correctly classified 1’-hydroxysafrole as a non-
mammary carcinogen based on 12 structural alerts associated with mammary tumorigenesis 
in other compounds in the mouse MC-NMC learning set (Figure 4.9). Based on these 
findings, it was noted that the inactivity of the non-mammary carcinogen, 1’-hydroxysafrole, 
is due in large to the compound’s benzyl ring.  Furthermore, it was noted that the oxygen-
containing parts of the molecule were excluded as significant inactive fragments. It is more 
than likely that the electron-withdrawing effect of the five-membered ring contributes to the 
23% chance of activity. It was noted that all 12 fragments had included mostly 1 or 2 active 
components. As a result, 1’hydroxysafrole was predicted to have a 77% probability of being 
a mouse non-mammary gland carcinogen.  
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Table 4.20 Fragments from the ABC 3/0.75 model leave-one-out validation analysis used to 
predict the inactivity of the mouse non-mammary gland carcinogen 1’-hydroxysafrole. 
  
Fragment No. Active No. Inactive Total % Active % Inactive 
      
79 1 5 6 0.167 0.833 
80 1 5 6 0.167 0.833 
81 1 5 6 0.167 0.833 
82 1 5 6 0.167 0.833 
83 1 5 6 0.167 0.833 
86 1 6 7 0.143 0.857 




















































Figure 4.9 Illustration of the 12 significant fragments contributing to the inactive validation 





The synthetic estrogen, diethylstilbestrol (DES) is a drug that was prescribed to 
pregnant women between the late 1930’s to early 1970’s to prevent miscarriages or early 
termination of pregnancy. However, physicians were advised by the Food and Drug 
Administration to discontinue its prescription due to its link to a rare from of vaginal cancer 
called clear cell adenocarcinoma. DES is a known human carcinogen (i.e., transplacental 
cancer) in the daughters of women that were exposed to this drug. DES is well documented 
to be a perinatal carcinogen in both humans and experimental animals. As described by 
Heneweer et al., “approximately 60% of all breast tumors are estrogen responsive and 
chemicals that show estrogenic or anti-estrogenic properties are able to interact with breast 
tumor growth. In a breast tumor, adipose stromal cells (fibroblasts) surrounding the epithelial 
tumor contain the aromatase enzyme, which converts androgens into estrogens.” (Heneweer 
et al 2004). It is this exposure to aromatase inducers that can then result in increased estrogen 
levels, which potentially can increase breast tumor growth. 
DES was selected to illustrate cat-SAR’s prediction of mouse mammary carcinogens 
based on the mouse MC-NMC model. DES has been tested in male and female mice and rats 
and has been observed to induce cancer in all four groups. This compound induces mammary 
tumors and cancer of the thyroid and pituitary gland in both male and female mice. However, 
DES is not classified as a Salmonella mutagen. Based on this compound’s classification in 
the CPDB, DES induces cancer of the adrenal and pituitary gland in male rats and the liver 
and pituitary gland in female rats. Additionally, DES induces testicular cancer in male mice 
and uterine and ovarian cancer in female mice. 
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Diethylstilbestrol was predicted to be a mouse mammary carcinogen based on its 
possession of 17 structural alerts (Figure 4.10). Based on these findings, the presence of the 
two phenolic hydroxyl groups seem to be responsible for the toxicological activity of the 
compound (i.e., a “neighboring effect”). Each of the seventeen fragments was found in three 
to five other compounds in the learning set, all of which induced mammary tumorigenesis. 
However, fragment 1115 also included 1 inactive component. Therefore, diethylstilbestrol 
was predicted to have a 98.6% probability of being a mouse mammary gland carcinogen 
(Table 4.21). 
 
Table 4.21 Fragments from the ABC 3/0.75 model leave-one-out validation analysis used to 
predict the activity of the mouse mammary gland carcinogen diethylstilbestrol (DES). 
  
Fragment   No. Active No. Inactive Total % Active % Inactive 
      
Frag1115  4 1 5 0.800 0.200 
Frag1223 3 0 3 1.000 0.000 
Frag2002 3 0 3 1.000 0.000 
Frag2003 4 0 4 1.000 0.000 
Frag2004 4 0 4 1.000 0.000 
Frag2005 4 0 4 1.000 0.000 
Frag2006 4 0 4 1.000 0.000 
Frag2007 4 0 4 1.000 0.000 
Frag2010 3 0 3 1.000 0.000 
Frag2011 3 0 3 1.000 0.000 
Frag2014 4 0 4 1.000 0.000 
Frag2017 4 0 4 1.000 0.000 
Frag2024 5 0 5 1.000 0.000 
Frag2025  5 0 5 1.000 0.000 
Frag2034 5 0 5 1.000 0.000 
Frag2047 5 0 5 1.000 0.000 
Frag2060 5 0 5 1.000 0.000 
 






























Figure 4.10 Illustration of the 17 significant fragments contributing to the active validation 
prediction of the mouse mammary carcinogen diethylstilbestrol. 
 
  4.1.6.9 Capsaicin 
  
 Capsaicin was selected to illustrate the cat-SAR predictions of mouse carcinogens in 
the CPDB general mouse model. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a quinone 
that has been shown to regulate a wide variety of activities that require NF-kappa B 
activation (Singh et al 1996). This is important because viral replication, immune regulation, 
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and induction of various inflammatory and growth-regulatory genes require activation of a 
nuclear transcription factor (NF)-kappa B. Agents, such as capsaicin, that can block NF-
kappa B activation have potential to block downstream responses mediated through this 
transcription factor (Singh et al 1996). There is evidence that capsaicin may have 
carcinogenic potential in humans and in biological systems designed to model human cancer 
(Azizan and Blevins 1995).  Both positive and negative effects have been found in classical 
genetic toxicology assays with capsaicin. However, the capsaicin tested in most studies has 
been derived from pepper plant extracts, which is likely to display varying degrees of purity 
and possibly diverse impurity profiles (Chanda et al 2004). 
 Capsaicin was predicted to be a mouse carcinogen based on the possession of 10 
structural alerts associated with mouse carcinogenesis in other compounds in the learning set 
(Figure 4.11). Each of these fragments was present in three other compounds in the dataset, 
all of which were mouse carcinogens (Table 4.22). Furthermore, all structural alerts were 
derived from the benzyl ring of the compound’s structure suggesting that aromaticity may 
play a role in the carcinogenicity of this compound.  
Table 4.22 Fragments from the ABC 3/0.90 model leave-one-out validation analysis used to 
predict the activity of the mouse carcinogen capsaicin. 
  
Fragment   No. Active No. Inactive Total % Active % Inactive 
      
Frag7465 3 0 3 0.800 0.200 
Frag7466 3 0 3 1.000 0.000 
Frag7467 3 0 3 1.000 0.000 
Frag7469 3 0 3 1.000 0.000 
Frag7470 3 0 3 1.000 0.000 
Frag7474 3 0 3 1.000 0.000 
Frag7475 3 0 3 1.000 0.000 
Frag7476 3 0 3 1.000 0.000 
Frag7477 3 0 3 1.000 0.000 
Frag7480 3 0 3 1.000 0.000 
 







































Figure 4.11 Illustration of the 10 significant fragments contributing to the active validation 
prediction of the mouse carcinogen capsaicin. 
 
4.1.6.10 1-Trans-delta-9-tetrahydrocannabinol (∆9-THC) 
 
 1-Trans-∆9-tetrahydrocannabinol (∆9-THC) was selected to illustrate cat-SAR 
predictions of mouse carcinogens based on the mouse carcinogenesis model. According to 
this compound’s classification in the CPDB, ∆9-THC is not a Salmonella mutagen. This 
compound has been tested in male and female rats and mice and has not been observed to 
induce cancer in any of these groups. 
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Based on findings from the cat-SAR study, nucleophilicity may play a major role in 
the non-carcinogenic effect of this major component of marijuana. Other studies 
demonstrated the importance of the A-ring aryl C-3 side chain and phenolic hydroxyl 
substituents, and elucidated the importance of a C-ring hydroxyalkyl substituent in 
cannabinoid toxicity (Melvin et al 1993). Melvin et al examined the structure-activity 
relationship surrounding this region (D-ring) of the molecule that is not present in the 
structure of ∆9-THC and other classical cannabinoid compounds. Both rigid fused ring benzo 
and cyclohexyl derivatives (i.e., creating the D-ring) retained binding affinity for the 
cannabinoid receptor. Extension of ketone or hydroxyl substituents from the C-2 position of 
the D-ring resulted in a 3-fold increase in binding affinity over the unsubstituted structure. 
However, the fused ring structure is not critical for the interaction with the receptor in as 
much as opening the ring did not decrease the potency. Extension of the D-ring C-2 alcohol 
by one carbon in length resulted in a pair of structures, for which the greatest affinity for the 
CB1 receptor occurred for the hydroxymethyl group in the axial conformation. 
The National Toxicology Program (NTP) performed carcinogenesis studies of ∆9-
THC in rats and mice and concluded that under the conditions of their 2-year gavage studies, 
there was no evidence of carcinogenic activity of ∆9-THC in male or female rats (NTP 
1996). However, there was equivocal evidence of carcinogenic activity of ∆9-THC in male 
and female mice based on the increased incidences of thyroid gland follicular cell adenomas 
when administered at 125mg/kg (NTP 1996). Increased incidences of thyroid gland follicular 
cell hyperplasia occurred in male and female mice, and increased incidences of hyperplasia 
and ulcers of the forestomach were observed in male mice (NTP 1996).  
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∆9-THC was predicted to be a mouse noncarcinogen based on the possession of six 
fragments (Figure 4.12). Each of the six fragments was found in three other compounds in 
the mouse learning set, all of which were mouse noncarcinogens (Table 4.23). ∆9-THC is 
therefore predicted to have a 100% probability of being a mouse noncarcinogen. 
Table 4.23 Fragments from the ABC 3/0.90 model leave-one-out validation analysis used to 
predict the activity of the mouse noncarcinogen 1-trans-delta-9-tetrahydrocannabinol. 
  
Fragment   No. Active No. Inactive Total % Active % Inactive 
      
Frag2456 0 3 3 0.000 1.000 
Frag2465 0 3 3 0.000 1.000 
Frag2474 0 3 3 0.000 1.000 
Frag2481 0 3 3 0.000 1.000 
Frag2489 0 3 3 0.000 1.000 
Frag2539 0 3 3 0.000 1.000 
 






















Figure 4.12 Illustration of the 6 significant fragments contributing to the inactive validation 




Acetohexamide (DymelorTM) was selected to illustrate cat-SAR prediction of rat 
carcinogens based on the rat carcinogenesis model. This compound has been tested in male 
and female rats and mice and has not been observed to induce cancer in any of the four 
groups. Also, acetohexamide is not classified as a Salmonella mutagen. DymelorTM is a 
popular sulfonylurea (SUR) drug in commerce used in the treatment of diabetes (an oral 
antidiabetic drug). There are currently 6 sulfonylureas on the market in the U.S. and almost 
1200 SURs in existence. Acetohexamide like other sulfonylurea drugs (i.e., tolbutamide, 
chlorpropamide, and tolazamide) are first-generation sulfonylureas. In comparison to first-
generation sulfonylureas, second-generation sulfonylureas (i.e., glyburide, glipizide and 
glibornuride) have a more non-polar or lipophilic side chain, which results in a marked 
increase in their hypoglycemic potency.  
The sulfate (-SO4) component of this chemical structure appears to be the major 
component contributing to the overall inactive behavior of acetohexamide and less to do with 
the ketone group within it structure. The results also suggest that the amino group attached to 
the sulfate group may play a critical role as to how the chemical may behave. The 
substituents that seem to enhance hypoglycemic activity are methyl, amino, acetyl, chloro, 
bromo, methylthio, and trifluoromethyl groups. The benzene ring should contain one 
substituent, preferably in the para-position. Additionally, the group attached to the terminal 
nitrogen should be of certain size and should impart lipophilic properties to the molecule. 
The N-methyl are inactive, N-ethyl have low activity, while N-propyl to N-hexyl are most 
active. Hypoglycemic activity is lost if N-substituent contains 12 or more carbons. Unique 
structural features include a p-acetyl moiety and a cyclohexyl group on the terminal urea.  
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The cat-SAR program predicted acetohexamide to be a rat noncarcinogen based on 
the possession of 20 structural alerts (Figure 4.13). All 20 fragments except fragment 8568 
were derived from other rat noncarcinogens. This fragment was identified as the O-C-N 
group. Fragment 8568 was not present in any other non-mammary carcinogen in the model. 
Instead, it was found in a total of three mammary carcinogens in the dataset. This fragment 
based on the total number of fragments in the model was associated with a 100% chance of 
being active. Interestingly, when compared to other similar significant fragments, namely 
fragments 11085, 11053, 11066, 11078, 11073, and 11061, the active structural feature 8568 
lacks the sulfate group. The significance of this finding is that of the deactivating effect of 
the sulfate group. Taken this into consideration, the compound was thus predicted to have a 
93% probability of being a rat noncarcinogen. 
Table 4.24 Fragments from the ABC 3/0.90 model leave-one-out validation analysis used to 
predict the activity of the rat noncarcinogen acetohexamide. 
  
Fragment   No. Active No. Inactive Total % Active % Inactive 
      
Frag8568 3 0 3 1.000 0.000 
Frag11041 0 3 3 0.000 1.000 
Frag11045 0 3 3 0.000 1.000 
Frag11049 0 3 3 0.000 1.000 
Frag11052 0 3 3 0.000 1.000 
Frag11053 0 3 3 0.000 1.000 
Frag11057 0 3 3 0.000 1.000 
Frag11060 0 3 3 0.000 1.000 
























































































































































Figure 4.13 Illustration of the 20 significant fragments contributing to the inactive validation 





 Bemitradine was selected to illustrate cat-SAR prediction of rat noncarcinogens based 
on the rat carcinogenicity model. According to bemitradine’s classification in the CPDB, this 
compound has only been tested in male and female rats. Bemitradine is a diuretic 
antihypertensive agent that has been shown to cause significant increases in the incidence of 
liver, thyroid (both sexes), and mammary (females only) neoplasms (Gad et al 1992). The 
metabolism of bemitradine was studied in both rats and humans. Bemitradine and its primary 
metabolite (SC-36741; desethylbemitradine) were tested and found to be non-genotoxic in 
Ames, rat primary hepatocyte UDS, CHO/HGPRT, CHO cytogenetics, in vivo mouse 
micronucleus and mouse lymphoma TK+/- (bemitradine only) assays (Gad et al 1992). 
Finally, in an altered hepatic foci (Y-glutamyl transpeptidase positive) promotion assay in 
female rats, bemitradine was found to be a promoter, though not as potent as phenobarbital. 
Gad and collaborators concluded that bemitradine (which has been dropped from 
development) is a non-genotoxic carcinogen that appears to act by a hormonally modulated 
promotional activity in inducing tumors in the liver and mammary glands. Tumors seen in 
the thyroid were probably secondary to the effects of bemitradine on metabolism (Gad et al 
1992).  
 The cat-SAR program identified mostly the double presence of the N-C-N atom of 
the triazine ring to be responsible for the compound’s overall carcinogenic effect. 
Bemitradine was predicted to be a rat carcinogen based on the possession of 10 significant 
fragments associated with rat carcinogenecity in other compounds in the dataset (Figure 
4.14).  Each of these fragments was found in three other compounds in the CPDB rat learning 
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set, all of which were rat carcinogens (Table 4.24). Bemitradine is therefore predicted to have 
a 100% probability of being a rat carcinogen. 
Table 4.25 Fragments from the ABC 3/0.90 model leave-one-out validation analysis used to 
predict the activity of the rat carcinogen bemitradine. 
  
Fragment   No. Active No. Inactive Total % Active % Inactive 
      
Frag5998 3 0 3 1.000 0.000 
Frag5999 3 0 3 1.000 0.000 
Frag6000 3 0 3 1.000 0.000 
Frag6009 3 0 3 1.000 0.000 
Frag6022 3 0 3 1.000 0.000 
Frag6023 3 0 3 1.000 0.000 
Frag6024 3 0 3 1.000 0.000 
Frag6050 3 0 3 1.000 0.000 








































































Figure 4.14 Illustration of the 10 significant fragments contributing to the active validation 
prediction of bemitradine. 
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 4.1.7 Mechanistic Analysis 
 
Analyses of the datasets by the cat-SAR expert system resulted in the derivation of 
good, explanatory correlations (or the lack thereof) between various toxicological 
phenomena such as mutagenesis, rodent, female and mammary-specific carcinogenesis and 
estrogenicity. The CDA was utilized to determine relationships (if any) and common 
biological effects between the toxicological endpoints studied. The mouse mammary 
carcinogen models were excluded from the CDA analyses due to it small population of 
chemicals. 
The possible mechanistic overlap between carcinogens, estrogens, and Salmonella 
mutagens was investigated. Based on the CDA analyses, there was a 43.6% correlation 
between the rat and female rat models (Analysis 1, Table 4.26). This was not unexpected 
considering the rat female learning set was built from the CPDB rat dataset. It was also 
reasonable to presume that a positive correlation would be observed between both the rat and 
female models with the rat mammary carcinogen models for the same reason (i.e., rat MC-
NC and MC-NMC models are both subsets of the general rat model). However, the rat 
mammary models are not exact subsets of the female rat carcinogen model because it 
included a few male-only breast carcinogens. This, however, should not curtail the model 
from positively correlating with the female model because only a few chemicals in the 
mammary carcinogen models were considered male-only breast carcinogens. Hence, the rat 
MC-NC model had a 72.4% (p<0.0001) (Analysis 2, Table 4.26) and 138% (Analysis 3, 
Table 4.26) correlation with the rat carcinogen and rat female carcinogen models, 
respectively. Due to this positive correlation observed between these models it was 
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concluded that there is a relationship between the female rat carcinogen, rat carcinogen, and 
the rat MC-NC models. 
When examining the CDA analyses for similarity of the rat MC-NMC model with 
other toxicological models the following information was derived. First, the rat MC-NMC 
model when compared to the rat MC-NC model, correlated to a lesser extent with the rat 
carcinogen model (19.3%) (Analysis 4, Table 4.26). Secondly, an insignificant (p=0.032) 
correlation was reported when examining the mechanistic overlap between the rat MC-NMC 
and the female rat carcinogen models (11.4%) (Analysis 5, Table 4.26). This indicates that 
these two models differ significantly and may be exhibiting their biological effects via 
different mechanisms. Lastly, the rat MC-NMC model also showed an insignificant 
(p=0.010) relationship to the MC-NC model. There was only a 13.6% similarity between 
these two models (Analysis 6, Table 4.26) suggesting that these two models are different. 
This also suggests that there is a difference between the rat MC-NC and MC-NMC models.  
This was logical considering the rat MC-NMC model is illustrative of the underlying 
mechanism in which carcinogens are breast carcinogens and the MC-NC model depicts how 
a substance is carcinogenic. 
For the CDA analyses looking at the relationships between Salmonella mutagenicity 
and other carcinogen models, a strong positive and significant correlation was shown. 
However, the rat MC-NMC and Salmonella models were not similar and had a high degree 
of insignificance associated with it (p=0.961). A –0.2% overlap was observed between the 
two models (i.e., a negative correlation) (Analysis 10, Table 4.26). This non-correlation was 
explainable. It was speculated that the rat NC-NMC model showed no correlation with the 
Salmonella mutagenicity model due to mutagens being found on both side of the model. In 
 95
other words, it was believed that the presence of carcinogens on both sides of the model was 
responsible for the dissimilarity, and under the model assumption (i.e., dogma) that 
Salmonella mutagens are carcinogens it seems logical that any out-standing electrophiles 
would be found as they are incorporated into both sides of the model. The Salmonella 
mutagenicity model had a 50.5%, 138.2%, and 128.8% overlap with the rat carcinogen, 
female rat carcinogen, and rat MC-NC models, respectively (Analysis 7-9, Table 4.26).   
Basically, the ESCREEN assay measures estrogen-induced growth of human MCF-7 
breast cancer cells. This assay is well characterized and estrogenic responses of chemicals are 
reported using two unique parameters (i.e., relative proliferative potency (RPP) and relative 
proliferative effect (RPE)) (Cunningham et al 2004). RPP compares the estrogenic potency 
of a compound to the potency of the standard estrogen 17-β-estradiol (Cunningham et al 
2004). On the other hand, it is realized that many estrogenic compounds, no matter how high 
the dose, will never produce cell proliferation at the rate of 17-β-estradiol (Cunningham et al 
2004). The RPE measures this effect. 
When looking at estrogenic relationships to other toxicological phenomena in the 
CDA analysis, it was shown that estrogens are less likely than random to be Salmonella 
mutagens or carcinogens (Analysis 11-15, Table 4.26). Consistent with the models, 
Salmonella mutagens were not estrogens and estrogens were not carcinogens. It was 
suggested that since carcinogens overlapped significantly with Salmonella mutagens and 
showed a negative correlation with estrogens that rat carcinogens may be exhibiting their 
carcinogenic effect mostly through mutagenesis and estrogens might be carcinogenic via 
some unidentified mechanism. This conclusion was reasonably drawn because the 
ESCREEN models also failed to denote any correlation with Salmonella mutagens.  
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Interestingly, this outcome was also shown with the MCASE program. It was 
classically thought that because estradiol and diethylestradiol (DES) carcinogenic 
mechanisms involved the reduction of electrons, thus producing hydroxyl ions, that estrogens 
were carcinogens via mutagenesis. This, in fact, might not be the case. The cat-SAR 
ESCREEN RPE model did not overlap with that of the cat-SAR or MCASE rat and mouse 
carcinogenicity models. Based on the results, breast carcinogens are not necessarily 
environmental estrogens and the rat MC-NMC model is finding a unique underlying 
mechanism of breast carcinogenesis that must be further investigated. 
The CDA analysis identifying the common underlying mechanisms (if any) between 
three toxicological phenomena was also studied. First, the relationship between rat 
carcinogen, RPE, and Salmonella mutagenicity models were examined for mechanistic 
relatedness. It was found that there were no positive (i.e., -2.3% overlap) or significant 
(p=0.743) relationships between cancer-inducing chemicals in rats, estrogens, and 
Salmonella mutagens (Analysis 16, Table 4.26).  
Secondly, the female rat, RPE, and Salmonella toxicological endpoints were studied 
for common mechanistic attributes. Interestingly, although the rat female model was simply a 
subset of the rat model, a positive correlation was observed when jointly analyzing the rat 
female carcinogen, RPE, and Salmonella mutagenicity models (p=0.001). A 31.8% overlap 
was noted (Analysis 17, Table 4.26). This outcome could not be explained. The rat MC-NC, 
RPE, and Salmonella models had a significant (p <0.0001) overlap of 44.1% (Analysis 18, 
Table 4.26). There was a significant negative correlation (i.e., -75.4%) observed between the 
MC-NMC, RPE, and Salmonella models (Analysis 19, Table 4.26). 
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Overall, the cat-SAR program is working well. As evidence, the well-tested 
compounds, caffeine and DES, were reported by cat-SAR as inactive compounds for 
Salmonella mutagenicity and for the ESCREEN RPE model caffeine was inactive, but DES 
based on its chemical structure was found to be positive for estrogenicity. This suggests that 
our models are able to distinguish between estrogens and carcinogens. Moreover, an 
additional CDA analysis of the various toxicological endpoints with Salmonella non-
mutagens, although not shown in the table, presented just the opposite of the Salmonella 
mutagens. In other words, a negative correlation was noted for each endpoint.  
Additionally, an analysis of the Salmonella mutagenicity data on active and inactive 
categories of the rat MC-NC and MC-NMC models was conducted to determine the degree 
of mutagenicity associated with each. In light of the active categories, 61 of the 73 rat MC-
NC and MC-NMC carcinogens evaluated for Salmonella mutagenicity were mutagenic (i.e., 
83.6%). These results were consistent with the findings by Gold and collaborators who 
observed 79% of mutagens to be carcinogens and 49% of non-mutagens as carcinogens. In 
other words, mutagens are more likely to be carcinogenic than nonmutagens.   
When analyzing the mutagenicity of the “inactive” category of the rat MC-NMC 
model (i.e., NMC), it was observed that 57.3% of the model’s 75 carcinogens (or 
nonmammary carcinogens) evaluated in the Salmonella assay were mutagenic. However, 
when evaluating the inactive (i.e., NC) category of the rat MC-NC model, 21% of the 
model’s 66 noncarcinogens were mutagenic. This suggests that when comparing the 
“inactive” categories of the rat MC-NC and MC-NMC models, a higher degree of 




Table 4.26 Mechanistic relationships of the cat-SAR rat mammary carcinogen models and 
other rodent carcinogenicity, Salmonella mutagenicity, and estrogenicity models.  
Analysis Observed Expected ∆* 100∆/Expected p-value 
1.  Rat + F-Rat 1166 812 354 43.6 <0.0001 
      
2.  Rat + Rat MC-NC 1410 818 592 72.4 <0.0001 
3.  F-Rat + Rat MC-NC 1202 505 697 138.0 <0.0001 
      
4.  Rat + Rat MC-NMC 1335 1119 216 19.3 <0.0001 
5.  F-Rat + Rat MC-NMC 769 690 79 11.4    0.032 
      
6.  Rat MC-NC + Rat MC-NMC 791 696 95 13.6    0.010 
      
7.  Rat + Salm 1537 1021 516 50.5 <0.0001 
8.  F-Rat + Salm 1648 692 956 138.2 <0.0001 
9.   Rat MC-NC + Salm 1595 697 898 128.8 <0.0001 
10. Rat MC-NMC + Salm 
 
11. Rat + ESCREEN RPE 
12. F-Rat + ESCREEN RPE 
13. Salm + ESCREEN RPE 
14. Rat MC-NC + ESCREEN RPE 
15. Rat MC-NMC + ESCREEN RPE 
 
16. Rat + RPE + Salm 
17. F-Rat + RPE + Salm 
18. Rat MC-NC + RPE + Salm 
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Observed:  Number of compounds simultaneously identified to be estrogens using the RPE model and the row-
listed endpoint. 
Expected:  The product of the individual prevalences of compounds identified to be estrogens using the RPE 
model and the row-listed endpoint. 
p-value:  Difference of two means test. 
∆:  Difference of observed from expected. 
100∆/Expected:  Percent difference from expected. 
 
4.1.7.1 Similarities in Mechanistic Relatedness: cat-SAR and MCASE 
 
 Upon evaluating the CDA analyses of the cat-SAR models, it was noted that the 
model results for various toxicological phenomena were consistent with that of the widely 
accepted commercial program MCASE.  This served as a great indicator that our models 
were indeed capable of making valid predictions and model interpretations. The MCASE and 
cat-SAR Salmonella mutagenicity models presented the highest degree of similarity. The 
results showed a 103.4% overlap occurring between the MCASE and cat-SAR Salmonella 
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models (Analysis 3, Table 4.27). Additionally, significant correlations were observed 
between MCASE and cat-SAR models for the following endpoints: rat carcinogenesis 
(28.8%), mouse carcinogenesis (89.1%), ESCREEN RPE (65.7%), and RPP (31.2%) models 
(Analysis 1,2,4, and 5, Table 4.27).  
Table 4.27 Comparison of measures of mechanistic similarities between cat-SAR models of 
CPDB rat and mouse carcinogenicity, ESCREEN RPE and RPP and Salmonella 
mutagenicity, and MCASE models of the same toxicological phenomena. 
Analysis  Observed Expected ∆ 100∆/Expected (%) p-value 
1. ESCREEN relative proliferative potency (RPP) 1068 814 254 31.2 <0.0001 
2. ESCREEN relative proliferative effect (RPE) 827 499 328 65.7 <0.0001 
3. Salmonella mutagenicity 2054 1010 1044 103.4 <0.0001 
4. CPDB rat 1623 1260 363 28.8 <0.0001 
5. CPDB mouse 1199 634 565 89.1 <0.0001 




4.2.1 Data Interpretation 
It is of great importance to note that the reproducibility of approximately 75%, as 
attained by Gold and collaborators in the rodent bioassay, may be the upper limit of accuracy 
reachable by any SAR model. In other words, regardless of how many times the model is 
evaluated it is never expected to be more than 75% accurate. From this perspective, given the 
mechanistic complexity of the carcinogenicity phenomena, the cat-SAR CPDB rat and mouse 
models that were 70% predictive is a respectable performance. The validation results for such 
models reflected a reasonably high prediction and explanatory power.  
It was also observed that some of the test compounds that underwent evaluations for 
mammary gland carcinogenicity in rats were identified as aromatic amines (e.g., 
hexamethylmelamine, o-toluidine, N-methylaniline), some of which were monocyclic 
aromatic amines. For example, the chemical o-toluidine is a mammary carcinogen in female 
rats. It may also be fair to say that this particular class of compounds may be exerting its 
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effect through the same mechanism. However, based on the mammary databases, not all 
chemicals within a specific chemical class induced mammary gland cancer. The mammary 
carcinogen database also included some halogenated and epoxide-forming chemicals. This is 
of particular significance because the pathogenesis of mammary gland neoplasia in the rat is 
similar to that in humans (Dunnick et al 1995). 
Although the described method relied heavily on the fragments, some of which were 
identified as structural alerts, the overall accuracy of the model was comparable to that of 
biologically based models. The study results clearly provide a plausible structural 
explanation as to not only why certain chemicals may be carcinogenic or non-carcinogenic, 
but also why they may be tissue or organ-specific. In addition, this study did not support the 
hypothesis that environmental estrogens may play a role in the etiology of mammary gland 
cancer. This was a significant finding as several studies within recent years have 
hypothesized that endocrine disruptors and particularly xenoestrogens are etiologic factors in 
an increased incidence of breast cancer (Lickley et al 2000; Hunter et al 1997; Pieter van’t 
Veer et al 1997; Falck et al 1992; Wolff et al 1995; Wasserman et al 1976). Synthetic 
chemicals with estrogenic activity (xenoestrogens) and organochlorine environmental 
contaminants polychlorinated biphenyls (PCBs) and DDE have been the prime etiologic 
suspects. In other words, estrogen-receptor-mediated mechanisms may be responsible for 
breast cancer development. However, the results from this study suggests otherwise. It was 
noted that only a few (i.e., less than 5%) chemicals comprising the mammary carcinogen 
datasets were estrogenic compounds. This may explain the lack of correlation between the 
estrogenicity and breast carcinogenicity endpoints. In contrast, strong correlation was 
observed between Salmonella mutagenicity and breast carcinogenicity. In other words, the 
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chemicals identified as mammary carcinogens in rodents were frequently Salmonella 
mutagens.   
 In support of this significant finding, Safe et al. noted that the results of a large 
number of studies from several countries on levels of PCBs (total) and DDE in breast cancer 
patients versus controls clearly demonstrate that levels of DDE and total PCBs are not 
significantly higher in breast cancer patients versus controls (Safe 2004). Furthermore, many 
of these studies contained large number of patients, and it was evident that differences in 
PCB and/or DDE levels in breast cancer patients versus controls initially reported in small 
cohorts in Connecticut (Falck et al 1992) and New York (Wolff et al 1993) were not 
subsequently observed in other states/countries (Safe 2004). Gammon and others whose 
studies focused on the potential linkage of PCBs and DDE and breast cancer in breast cancer 
patients in Long Island, New York, concluded that “these findings, based on the largest 
number of samples analyzed to date among primarily white women, do not support the 
hypothesis that organochlorines increase breast cancer risk among Long Island women” 
(Gammon et al 2002) (Safe 2004). Hence, the endocrine disruptor hypothesis regarding the 
induction of mammary gland cancer suggests that exposure to weak environmental estrogens 
does not play a role in the development of breast cancer. 
4.2.2 Strengths and Weaknesses of cat-SAR 
 
The strength of cat-SAR lies in its capacity to find the link between predictions and 
the reproducibility of rodent cancer bioassays and short-term assays, even in the case of 
unknown relationship. The data analyses unveil the usefulness of this approach in 
differentiating between carcinogens and noncarcinogens, and mammary carcinogens and 
non-mammary carcinogens. This research confirms the feasibility of cat-SAR for predicting 
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carcinogenicity of chemicals. This expert system’s characteristic of being able to identify not 
just the active fragments of a chemical contributive to its carcinogenic effect but its inactive 
fragments contributing to a ‘noncarcinogenic’ effect may not be new to the real world, but it 
is new the field of computational toxicology and SAR modeling. This makes it possible to 
study the underlying mechanistic pathways of breast cancer and anti-cancer. 
The models developed using our new program’s methodology has proven to work on 
levels equivalent to and in some cases, better than some other existing SAR programs. Our 
approach can usefully complement the results of the rodent bioassay. A common weakness of 
the cat-SAR expert system was that it incorrectly identified some very well known inactive 
compounds as active. Moreover, a few of the most popular powerful carcinogens were 
predicted to be inactive. At times, it was observed that particular groups or fragments of a 
test compound shared the same properties of a class of compounds that were not shown by 
that particular compound in its entirety. Another weakness uncovered in the program was the 
exclusion of possible structural alerts.  These groups may have been associated with 
aromaticity, electrophilicity and nucleophilicity. It is possible that there may have been a 
significant group influencing the chemical’s overall activity. However, this fragment group 
may have been unique with respect to the entire group of fragments in the data set and thus, 
as a rule, excluded from the final fragment set. As a result, the reported list of structural alerts 
may be incomplete. This may account for some of the wrong active or inactive chemical 
predictions. Most pitfalls surrounding the cat-SAR algorithm can be linked to the lack of 
information and structural or model uncertainties (Walker 2003) arising from the fact that 
every model is a simplification of reality. 
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 Additionally, cat-SAR faces a challenge commonly faced by expert systems. This 
phenomenon is the effect of neighboring groups. An identified structural alert may be 
exhibiting carcinogenic effect because of another structural feature on the compound. For 





















CHAPTER 5. SUMMARY AND CONCLUSIONS 
5.1 Summary 
The cat-SAR expert system was evaluated for its ability to predict and distinguish 
CPDB mammary-specific carcinogens and rodent carcinogens from non-mammary 
carcinogens and whole animal noncarcinogens. The validation trials were conducted using 
the LOO-CV procedure. The mammary carcinogen models developed herein improved SAR 
models in general, for predicting mammary carcinogenesis by considering chemicals that 
were carcinogens, but not mammary gland carcinogens, in the dataset. The study results 
demonstrate the usefulness of cat-SAR in predicting chemical toxicity for datasets of tested 
and untested compounds, with strength in its ability to predict mutagenicity over a wide 
range of chemical space, i.e. universal predictivity. The analyses of the predictions indicate 
that the concordance is equitably weighted in terms of the program’s ability to correctly 
predict mammary carcinogens and non-mammary carcinogens, whereas other SAR 
approaches tend to produce rodent data of uneven distribution of noncarcinogens favoring a 
significantly high specificity compared to its sensitivity (i.e., high number of false negatives). 
Additionally, the performance of the cat-SAR program in predicting CPDB mammary-
specific carcinogens appeared to be independent of the chemical utility of the compound, i.e., 
industrial, agricultural, or pharmaceutical.  
The rat and mouse mammary gland carcinogen models were an estimated 80% 
accurate and the general rodent models were both 70%.  Given the fact that predictive models 
will never achieve 100% overall accuracy because the animal bioassay results from which 
they are built are 75% accurate, it is reasonable to say that the cat-SAR program is 
performing at a respectable level. It was observed that the ABCH 3/0.90 models tend to be 
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more inclusive in terms of the number of test compounds predicted correctly. However, in 
comparison to the ABC 3/0.90 model for each dataset, the ABCH 3/0.90 models were more 
accurate overall in terms of its ability to predict the correct activity. Due to the small size of 
the mouse mammary carcinogen datasets it was presumed that this greatly influenced the 
favoring of the least restrictive model (i.e., ABC 3/0.75).  Thus, it was reasonable to 
conclude that for large learning sets the following concept applies: the more restricted the 
model, the more predictive and accurate the model.  However, for small datasets such as that 
of the mouse mammary carcinogen models, a less restrictive (i.e., ABC 3/0.75) model is 
preferred.  
5.2 Conclusions 
The application of the cat-SAR program has been demonstrated for outlining the 
performance characteristics of its predictive SAR models. It provided a rigorous and precise 
computational basis for making predictions and can be used by governmental agencies as 
well as industry as a starting point for predicting toxicity and ranking chemicals based on 
prediction results. The program has proven successful in use of similarity analysis from 
which an understanding of biological mechanisms that underlie adverse biological effects in 
humans and ecologically important species can strengthen. The cat-SAR program’s 
capability to identify organ-specific carcinogens makes it a unique and promising SAR 
approach. Moreover, the methodology presented herein could readily be expanded to other 
biological endpoints.  
The cat-SAR study showed that certain structure-activity relationships exist among 
mammary and non-mammary gland carcinogens. Several structural alerts believed to activate 
or deactivate mammary carcinogenesis have been identified. It was found that the amino azo 
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group was the most prominent structural feature among the mammary carcinogens. 
Furthermore, the results of this study suggest that there is no linkage between dietary or 
environmental estrogenic compounds and breast cancer. The underlying relationship between 
estrogenicity and carcinogenicity is intriguing and merits more detailed investigation, since it 
may provide new insights into the mechanisms that control mammary tumorigenesis. 
Lastly, the structural alerts identified were consistent in randomly selected 
noncarcinogen models derived from subsets of the rodent data suggesting confidence in an 
association between these parameters and mammary carcinogenesis. It should be noted that 
although the results reported herein indicate that structural features of certain mammary 
gland carcinogens contribute to their ability to induce mammary gland cancer in rodents, the 
model may not be relevant to human breast carcinogenicity as the data were derived from 
rodent data, rather than from human studies.  
The goal of accurate and reliable toxicity prediction for any chemical, based solely on 
structural information remains elusive. To predict, we must be able to rely on the accuracy of 
animal bioassays and generalize based on structural alerts. Evaluation of new SAR methods 
is needed due to the limitations on the current toxicity screening methods and heightening 
demands on regulatory processes. The challenge for the future will be to improve 
technologies for prediction within the constraints of available data, make optimal use of new 
test data, and better integrate elements of quantitative modeling (QSAR), empirical 
association, and biological and chemical mechanisms towards the goal of toxicity prediction 
(Richard 1998). SAR modeling of biological end-points is an empirical study and further 
research is required to determine the factors associated with the increasing incidence of 
breast cancer. 
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There are challenges involved in identifying and comprehending tissue-specific 
carcinogens. We have tested the rodent and mammary carcinogen models for its predictivity 
with the LOO-CV procedure and found it to be promising. The cat-SAR method is practical 
and it is to be used as a tool to assist in medical treatment of breast cancer. It is also believed 
that cat-SAR can be used in pinpointing those chemicals that really need attention. Therefore, 
prioritizing them for more costly and time-consuming in vivo assays required for the 
classification of carcinogens. 
Moreover, the cat-SAR rodent study is based on a broad spectrum of chemicals of 
various classes. As such, the models can be generalized based upon cross-validations. Lastly, 
the structural alerts identified suggest that DNA adduct formations and prohibitions of cell 
division may be important steps in breast cancer development. Further studies are needed to 
elucidate the mechanisms underlying estrogen-mediated influences in breast cancer 
development.  
5.3 Suggestions for Future Research Work 
Future research work, based on existing work, include, but not limited to the 
following: (1) Upon extensive review of the CPDB plot used in this study, it was observed 
that the mammary gland carcinogens for the rat and mouse were established by just a few in 
vivo experiments whose results provided the possibility of it being carcinogenic with respect 
to the mammary gland. It is likely that more animal cancer tests could in fact improve the 
quality and consistency of the data produced by enriching the learning set with new 
mammary carcinogens leading to the identification of new structural features. So 
theoretically, providing the cat-SAR expert system with the necessary data could improve 
model predictivity and enhance mechanistic understanding, however, in reality, due to the 
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high expense and time constraints associated with rodent cancer bioassays, this is very 
unlikely; (2) further studies into why a test compound was incorrectly predicted by the cat-
SAR program as active or inactive should be pursued.  Exploring this area could contribute to 
possible chemical and biological mechanisms; and (3) a distinction should be made between 
marginally active carcinogens and active carcinogens. The models evaluated in this study 
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